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Abstract
Alzheimer’s disease (AD) is an age related neurodegenerative disease with
pathology that includes amyloid plaques, neurofibrillary tangles and non-resolving
neuroinflammation. Non-resolving neuroinflammation lasts the entire course of the
disease and has deleterious effects and is often thought to accelerate AD pathology. NonSteroidal Anti-inflammatory Drugs (NSAIDs) have commonly been used as therapeutics
to treat pain, inflammation and vascular. NSAIDs work by altering the cyclooxygenase
(COX) mediated biosynthesis of prostaglandins which are lipid mediators that have many
physiological functions, for example nociception, inflammation and vasodilation.
Epidemiological studies support the notion that NSAIDs could be used to treat AD. Yet,
clinical trials using NSAIDs have failed repeatedly. Therefore, the effectiveness of
NSAIDs is likely counterproductive by blocking the production of neuroprotective as well
as neurotoxic prostaglandins. Many people are also intolerant to extended NSAID use
shown to increase the risk of other diseases. A more specific approach is necessary to
reduce side effects and optimize effectiveness. One such approach that I investigated in
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the studies reported here, is to target downstream of the COX enzymes, specifically
prostaglandin signaling including their receptors. Prostaglandin D2 (PGD2) is particularly
of interest because PGD2 is the most abundant prostaglandin in the brain and increases
the most under pathological conditions. PGD2 signals through prostaglandin
D2 receptor 1 (DP1) and receptor 2 (DP2). Interestingly, PGD2 signaling is well
established to be one of the main drivers of inflammation in diseases of airway
inflammation.
As an alternative to PGD2 signaling to treat AD, I explored a combination drug
treatment strategy. AD is a multifactorial disease for which therapeutic efficacy should
benefit from a multi-target approach. Thus, I tested a combination treatment with
diazoxide (DZ) and dibenzoylmethane (DIB). DZ is a potassium channel activator. DIB
restores eIF2B activity, thus reversing stress-induced translational depression. Previous
studies examined each drug’s individual therapeutic benefits on attenuating
neurodegeneration and apoptosis in other animal model systems. However, their
combined treatment potential was not addressed.
The overall goal of my studies was to investigate novel therapeutic strategies to
treat AD. Thus, I examined novel options to treat AD (1) by targeting PGD2 signaling with
timapiprant (TIMA), an antagonist of its DP2 receptor, and (2) by using a co-treatment
therapy with DZ and DIB, to investigate a polypharmacology strategy.
My hypothesis is that manipulating PGD2 signaling or using a combination
DZ/DIB drug treatment will effectively slow down the progression of AD pathology. To test
my hypothesis, I used the transgenic TG-AD Fisher 344 rat model of AD (Tg-AD). Tg-AD
rats develop multiple hallmarks of AD including plaques, tangles, neuronal loss,
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neuroinflammation and cognitive deficits in an age-dependent progressive manner that is
comparable to human AD. Most of my studies included 11-month old rats, because at this
age the Tg-AD rats exhibit most (moderate) of the full AD-pathology (goal 1). Some of my
studies (goal 3) also used rats at 4 months of age to be able to compare this pre-pathology
stage with the moderate-pathology at 11-month old rats.
Goal 1: Investigate PGD2 signaling and test the therapeutic efficacy of its
anti-inflammatory DP2 receptor antagonist TIMA in a transgenic rat model of AD
(Chapter 2).
Firstly, I found by mass spectrometry that PGD2 levels in hippocampi of transgenic (TG)
and wildtype (WT) littermates were the highest of the prostaglandins measured, i.e.
PGD2, PGE2, and PGJ2, as well as thromboxane B2. Secondly, I determined by
immunohistochemical analysis that microglial DP1 receptors were more abundant and
neuronal DP2 receptors were fewer in transgenic than in WT rats. Thirdly, I established
by RNA-sequencing analysis that expression of lipocalin prostaglandin D synthase
(LPGDS), the major brain PGD2 synthase, was the highest among 33 genes involved in
the PGD2 and PGE2 pathways. Finally, I treated a subset of rats (WT and TG males) with
TIMA, a potent highly selective DP2 antagonist in development for allergic inflammation
treatment. TIMA significantly mitigated AD pathology and cognitive deficits in transgenic
males. Based on my data, I conclude that selective DP2 antagonists have potential as
therapeutic agents for AD.
Goal 2: Human polymorphisms in the PGD2 pathway (Chapter 3).
I analyzed human genomic polymorphisms of the PGD2 pathway, namely DP1, DP2,
LPGDS and Hematopoietic Prostaglandin D Synthase (HPGDS), previously published by
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others. In addition, I analyzed human polymorphisms linked to NSAID treatment efficacy.
These analyses discussed below in Chapter 3.2, are useful to predict the efficacy of
administering drugs that target the PGD2 pathway and as well as NSAID efficacy to treat
AD.
Goal 3: Investigate the effects of DZ/DIB co-treatment on spatial memory and
transcriptome of a transgenic rat model of AD (Chapter 4).

In this study, I compared spatial memory and gene expression of 4-month (prepathology) and 11-month (moderate-pathology) Tg-AD rats and WT littermates.
Using the radial 8-arm maze (RAM) to evaluate spatial learning I found that (1) at
4-months of age there were no spatial memory deficits in Tg-AD rats, (2) at 11-months of
age WT rats performed significantly better than Tg-AD rats, (3) at 11-months of age TgAD rats treated with DZ/DIB performed significantly better than non-treated Tg-AD rats,
(4) at 11-months of age WT rats treated with DZ/DIB performed better than non-treated
WT rats. Based on this data I conclude that DZ/DIB treatment not only mitigates spatial
memory deficits of the Tg-AD rats, but also improves spatial memory of WT rats.
Using RNA sequencing analysis to evaluate the expression of 17,168 genes under
different conditions, I found that (1) non-treated 4-month WT and Tg-AD female rats
differed significantly in the expression of the following 4 genes: EGR2, HISIT1H2AA, APP
and PSEN1; (2) at 4-months of age Tg-AD treated and not-treated female rats differed
significantly in the expression of the following 8 genes: TTR, OLFM3, CNTN6, NDST4,
IRF6, SLC17A6, APP and PSEN1; (3) non-treated 11-month WT and Tg-AD female rats
differed significantly in the expression of the following 4 genes: RN7SL1, GFAP, APP and
PSEN1. These genes are related to cognition, neurogenesis, differentiation, synaptic
plasticity, apoptosis, and amyloid toxicity. The relevance of the changes observed in
vii

these genes is discussed below Chapter IV. Based on this data I conclude that DZ/DIB
treatment changes the expression pattern of some genes at the pre-pathology stage in
Tg-AD females.
The effects of the DZ/DIB combination treatment on Tg-AD rats was
complemented by studies carried-out by another graduate student in our laboratory,
Giovanni Oliveros. Giovanni investigated by immunohistochemistry, the effect of the
double drug treatment on AD pathology. Notably, the DZ/DIB treatment mitigated the
buildup of hippocampal Aβ plaques and neurofibrillary tau tangles in Tg-AD treated
compared to untreated Tg-AD rats. Together, our results strongly support that the
combination DZ/DIB treatment is an effective strategy to mitigate AD pathology due to its
multi-target approach that affects multiple signaling pathways.
Conclusion: My studies described here suggest that two novel therapeutic
approaches, i.e. TIMA by itself and the DZ/DIB combination, should be explored as novel
treatments to mitigate AD pathology.
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CHAPTER I

Introduction

1.a. ALZHEIMER’S DISEASE: PATHOLOGY
1.b. CYCLOOOXYGENASE PATHWAY: IMPLICATIONS IN AD
1.c. NOVEL THERAPEUTIC STRATEGIES TO TREAT AD
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1.a. ALZHEIMER’S DISEASE: PATHOLOGY
1.a.1. An overview of AD
Alzheimer’s disease (AD) is the most common form of dementia and is a rapidly
growing disease among the aging population. The main hallmarks that characterize AD
are amyloid plaques, neurofibrillary tangles, gliosis, synaptic and neuronal loss, as well
as neuroinflammation. Early-onset AD is considered to occur in individuals less than 65
years old that express mutations on genes such as presenilin (PSEN) 1/2 and amyloid
precursor protein (APP) that lead to increased Aβ deposits [1]. Most in vivo studies use
one or a combination of these mutations to produce an AD-like pathology in their model.
Late-onset AD is considered to occur after the age of 65, and the causes are
undetermined.
Reducing the risk prior to full AD pathology can be accomplished without
therapeutics by modifying certain lifestyle choices. AD is associated with some conditions
and life styles, such as vascular disease, type 2 diabetes, epilepsy, traumatic brain
injuries, depression, exercise, sleep, diet, tobacco use, and alcohol use [2]. For example,
increased risk of dementia in those with type 2 diabetes rises ~60% and those with more
than four traumatic brain injuries rises to ~183% [3, 4]. Another protective factor is
cognitive reserve which refers to the brain’s resilience through repeated frequent use of
cognitive processes to cope with cognitive dysfunction [5]. Interestingly, cognitive reserve
can be built up as early as childhood with social and sensory interactions such as
multilingual, education, career, motor skills, social networks, enrichment and more [6].
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Some of the cases for late-onset AD are associated with genetic mutations
discovered through Genomic-Wide Association Studies, and they affect cellular
processes. These mutations can primarily be placed in three categories: immune
response, cholesterol metabolism, and synaptic function [7]. My project focuses on the
immune response that leads to increased neuroinflammation in AD. Inflammation is
intended to be a beneficial response from the body that aids in the process of defending
or repairing itself in response to an insult. As an acute response, inflammation works to
find the insult and respond to it and then the inflammation is resolved. However, if the
inflammatory response is chronic and non-resolving it will have toxic effects to healthy
cells at the site of the inflammatory response. It is not clear whether in the brain,
neuroinflammation is the cause or the result of neurodegeneration, but it most likely leads
to its progression [8]. Neurodegeneration occurs in such conditions such as AD,
Parkinson’s Disease, stroke, traumatic brain injuries, neural viruses, neural cancers, and
multiple sclerosis [9]. The effects of the conditions mentioned above tend to lead to nonresolving inflammation, which lead to worse outcomes for the inflicted.

1.a.2. Microgliosis and AD
Microglia are resident macrophages of the brain as well as one of the primary
contributors of inflammation in the brain. Microglia morphology can be classified based
on soma size and process length. Morphology directly corresponds to their function:
ramified are resting/surveillance (healthy state), reactive are activated meaning
cytokine/chemokine/ROS/NO (intermediate state), and ameboid are always phagocytic
(clean up) [12]. Microglia activation leads to an overall increase in microglia as well as a
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shift away from the ramified state towards the reactive or amoeboid state which occurs
during pathological conditions. Pro-inflammatory markers for microglia include tumor
necrosis factor α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), iNOS (inducible
Nitric Oxide Synthase), nicotinamide adenine dinucleotide phosphate oxidase type-2
(NOX2), monocyte chemoattractant protein 1 (MCP1), superoxidase dismutase-1 (SOD1), and cyclooxygenase-2 (COX-2). However, microglia can also exhibit anti-inflammatory
markers including interleukin-4 (IL-4), interleukin-10 (IL-10), interleukin-13 (IL-13),
transforming growth factor β (TGF-β), arginase-1 (Arg1), insulin growth factor 1 (IGF-1),
and brain derived neurotrophic factor (BDNF) [10, 11]. Activated microglia that upregulate
pro-inflammatory mediators can accelerate neurodegeneration [11].

1.a.3 Spatial memory and the hippocampus
Cognitive abilities are impaired in AD, and many early signs of AD show problems
in memory. The hippocampus is involved in memory formation and consolidation such as
episodic and spatial memory. Episodic memory is a type of memory that refers to specific
events or experiences with a spatial memory context, and it is controlled by hippocampus
and nearby brain regions [13]. Other regions that input and aid in spatial memory include
the parahippocampal cortex and entorhinal cortex. The parahippocampal cortex has
afferent inputs to the entorhinal cortex (EC) which is commonly referred to as the gateway
into the hippocampus [14]. The EC is the major input to the hippocampus and this
connection is the start of the perforant pathway. In the perforant pathway, signals travel
throughout the subregions of the hippocampus. The hippocampus has major outputs from
the subiculum to the fornix and amygdala that are involved in memory. Fornix is a white
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matter structure that is involved in memory recall and the amygdala is closely tied to
emotional memories [15, 16].
The

subregions

of

the

hippocampus

include dentate gyrus (DG), Cornu Ammonis 1
and 3 (CA 1 and 3) and subiculum (SB). In my
studies, I analyze all of these subregions, but the
results highlight the pathology within the DG
where our lab has seen robust effects [17].
Primary flow of information through the DG is
through the perforant pathway from the afferent
projections to granule cells in the DG, which is later
passed to CA3. Within the DG, I focused on the

Fig. 1.1 The hippocampus is
important in memory formation
and is one of the earliest brain
regions to show AD pathology.
Subregions of are shown in this
figure as well as the basic flow of
signals [18].

granular cell layer (GCL) which is made up of the granular cells, and then the hilus which
consists of mossy cells and interneurons (Fig. 1.1)[18]. Overall, the DG circuitry
contributes to spatial memory formation, synaptogenesis, and synaptic plasticity [19, 20].
The border of the hilus and GCL is the subgranular cell layer which is a site of adult
neurogenesis in rodents, and is regulated by transcription factors like SRY-box
transcription factor 2 (Sox-2) [21]. Sox-2 expression is controlled by PGD2 signaling [22,
23]. Adult generated granule cells are important for new spatial memories, and a thinner
GCL indicates neuronal loss or impaired neurogenesis [24]. To access hippocampaldependent cognitive function, spatial tasks with environmental ques and navigation are
required. In my studies, I use two spatial-dependent behavioral tasks on the Tg-AD and
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WT littermates: (1) active place avoidance task (aPAT), and (2) the 8-Arm Radial Arm
Maze (RAM), further explained in the following Chapter 2.

1.a.4. Transgenic Fisher 344 rat model of AD
Preclinical models of AD are important, because they give us a better understanding for
treating complex diseases. Many preclinical animal models of AD use transgenes,
meaning that genes are inserted that will guarantee some form of AD pathology such as
genes related to amyloid A and tau. Some of these genes include mutations that mimic
AD: APP, PSEN1, PSEN2, Apolipoprotein E ε4 allele (APOEε4) and Microtubule
Associated Protein Tau (MAPT) [25]. Some of the models for AD such as the 5xFAD
mouse model have extremely rapid amyloid pathology where intraneuronal Aβ42 is seen
as early as 1.5 months of age [26]. For a disease where ageing is the most important risk
factor, such models do not take this into consideration. Therefore, our lab used the TGAD Fisher 344 rat model
of AD (Tg-AD).
The Tg-AD rats
have

two

transgenes

from early onset AD
driven

by

promoter:
Swedish
(APPswe)

the

prion

The

APP

mutation
and

a

Fig. 1.2 Tg-AD rats exhibit an age dependent progression some
early signs of AD like pathology. At 6 months of age Tg-AD rats
exhibit early signs of pathology, and by 16 months of age more
severe pathology.

presenilin 1 with deletion of exon 9 (PS1ΔE9). This model expresses a 2.6-fold increase
6

of human APPswe and a 6.2-fold increase of PSE1ΔE9 compared to the endogenous
respective rat genes [27]. With these mutations rats develop cognitive defects, elevated
soluble Aβ40, insoluble tau, and gliosis at 6 months of age [27]. At 11 months, our lab
observed Aβ deposition, tau hyperphosphorylation, gliosis, and spatial memory
impairments [28]. At 16 months of age, the rats develop neurofibrillary tangles (NFTs),
neuronal loss, intraneuronal Aβ42, sex-independent spatial learning deficits, and
apoptosis [27]. The blood brain barrier (BBB) permeability of Tg-AD rats was analyzed at
13, 18 and 21 months of age, but when compared to WT rats differences were only seen
at 18 months of age. The authors believe that AD pathology weakened the BBB at 18
months of age, and that ageing and AD effects on the BBB were indistinguishable by 21
months of age [29]. My studies investigate two timepoints at 11-months of age with
moderate pathology, and at 4-months of age pre-pathology with no amyloid, gliosis, or
cognitive pathology as observed in our lab.

1. b. CYCLOOOXYGENASE PATHWAY: IMPLICATIONS IN AD
1.b.1. Prostaglandin overview
Many chronic diseases are associated with non-resolving inflammation. For many of
them, inhibition of the COX pathway is a target to ameliorate excess inflammation.
Biosynthesis of prostaglandins by the COX pathway increases at the site of inflamed
tissue. Prostaglandins are bioactive lipids with hormone-like signaling properties that
belong to the eicosanoid family. While prostaglandins perform many roles throughout the
body, in the brain they mediate responses for fever, pain, inflammation, and sleep [30].
The backbone of prostaglandins is made up of 20 carbon atoms including a 5 membered
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carbon ring. The most common mammalian prostaglandins are the series two
prostaglandins. These prostaglandins are derived from arachidonic acid, which is
enzymatically cleaved from the cell membrane phospholipids by phospholipase A2.
Arachidonic acid can be further oxidized enzymatically or non-enzymatically through the
COX Pathway. COX isoenzymes known as COX-1 and COX-2, function to first synthesize
an unstable intermediate, PGG2, which is quickly reduced to PGH2. After PGH2
synthesis, the aid of multiple synthases can produce an array of prostaglandins and
thromboxane A2 products: PGI2, PGE2. PGF2α, PGD2, and Thromboxane A2 (TXA2).
Many of these prostanoids can be further metabolized and/or can bind to their respective
receptors. COX-1 is constitutively expressed to maintain homeostasis, yet COX-2 can be
induced by a variety of factors to increase prostaglandin biosynthesis which may increase
the inflammatory response [31]. COX-2 is expressed at higher levels in the AD brain and
in hippocampal neurons [26, 27].
Most of the studies on prostaglandins in AD focus on PGE2 specifically on PGE2’s
microglial inflammatory response in preclinical models of AD and other neurological
diseases [32]. However, PGD2 is the most abundant prostaglandin in the brain, so my
studies focus on PGD2’s role in AD. PGD2 is synthesized by hematopoietic-type PGD2
synthase (HPGDS) and by lipocalin-type PGD2 synthase (LPGDS). LPGDS is very
abundant in the brain and Cerebral Spinal Fluid (CSF), and it acts as the primary PGD2
synthase within the brain [33]. LPGDS has functions beyond PGD2 production and
directly connected to AD for example acting as a chaperone and disaggregase for Aβ
peptides [34]. HPGDS is expressed in macrophages and is upregulated within patient
plaques [35]. Within the mouse hippocampus, HPGDS is expressed higher in microglia
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compared to neurons and astrocytes
and in vitro microglia produce PGD2
through autocrine ROS activation of
HPGDS [36].
PGD2 receptors belong to the
protein family of G protein-coupled
receptors
regions

(GPCRs).
in
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have
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signaling cascade [37]. For DP1, the
intracellular domain interacts with Gs
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cAMP, leading to stimulation of cAMP
dependent Protein Kinase A (PKA) and

Fig. 1.3 PGD2 is produced from arachidonic acid
with the help of PLA2 and COX enzymes. In the
brain, LPGDS is the primary synthase for
converting PGH2 into PGD2. PGD2 can bind to
either the DP1 or DP2 receptors that have
inverse functions.

an influx of calcium into the cell driven by
(created with BioRender.com).

phosphorylation of L-type

Ca2+

channels
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[38][39]. For DP2, the intracellular domain interacts with Gi, which inhibits cAMP
production and leads to inositol triphosphate (IP3) mediated release of calcium ions from
the endoplasmic reticulum into the cytosol [31]. DP2 also belongs to a subclass of GPCRs
known as chemoattractant receptors that are involved in chemotaxis, and it is sometimes
referred to as chemoattractant receptor–homologous molecule expressed on TH2 cells
(CRTH2) [31]. PGJ2 is a metabolite of PGD2, and PGJ2 binds to the nuclear Peroxisome
proliferator- activated receptor γ (PPAR-γ) [40]. After ligands bind to PPAR-γ, the activity
of PPAR-γ is modulated which may have favorable or adverse effects such as changes
in adipogenesis, lipid metabolism, phagocytosis, inflammation, and many more [41].
1.b.2. Epidemiological evidence that NSAIDs decrease AD risk
The COX pathway is the target of widely used therapeutics known as NSAIDs, and
for AD the strategy is to reduce inflammation induced by the COX pathway. Common
NSAIDs that inhibit the COX enzymes and have been used in AD clinical trials are aspirin
and naproxen; these also both have shown disaggregase activity towards Aβ peptides
[42]. Aspirin uniquely has an irreversible mechanism that acetylates COX enzymes, which
has longer lasting effects on anti-platelet function and aspirin has slightly higher affinity
to the COX-1 enzyme [43]. Daily aspirin use is effective in lowering adverse vascular
events in high-risk patients [44]. In contrast, naproxen does not have increased COX-1
affinity, and because lowering platelet levels is not beneficial, many of the clinical trials
for AD shifted towards naproxen. Early observational or epidemiological studies
suggested that NSAIDs would reduce the risk of AD due to lower incidence of AD in
rheumatoid arthritis patients who regularly took NSAIDs to manage inflammatory
symptoms [45, 46]. However, when applied to clinical trials, findings have given mixed
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and messy results for outcomes, and when looking at pre-symptomatic patients with “late
old age” there is an increased risk for cognitive decline after naproxen use [47, 48].
Furthermore, naproxen does not meaningfully alter any markers for inflammatory immune
responses in the CSF after use [49]. Dosage, type of NSAID, severity of disease, APOE
ε4 status, age, and further heterogeneity of patients seems to play a role, but this is
challenging to interpret [47].
Safety after extended use has also been a concern for NSAIDS because studies
showed increased risk for gastrointestinal, renal, and cardiovascular complications [5052]. These increased risks were thought to stem predominantly from inhibiting COX-1
function, so NSAIDs specific to COX-2 inhibition were developed and termed as coxibs
such as celecoxib and rofecoxib [53]. Unfortunately, unselective NSAIDs and coxibs both
have increased risks for gastrointestinal, renal, and cardiovascular complications [54].
Coxibs also have not shown any benefits in clinical trials for AD [55, 56]. The failures in
clinical trials are confusing to investigators because NSAIDs were shown to reduce AD
pathology in rodent models [57]. In my view these drugs should not be disregarded
completely, but coxibs and traditional NSAIDs are not effective enough to be the primary
treatment to combat AD as originally hypothesized. However, the strategy of reducing
neuroinflammation still needs to be explored and I argue that downstream of the COX
enzymes merit investigation.
1.c. Novel Therapeutic Options for AD
1.c.1. Repurposing PGD2 targets for AD
PGD2 synthases: The synthases for PGD2 have inhibitors available which block
PGD2 production and other functions of these synthases [58, 59]. However, in the brain
11

LPGDS is the primary brain synthase and it is multifunctional including protective effects
of disaggregation mentioned earlier. HPGDS does contribute to neuroinflammation as
mentioned earlier [36], so perhaps inhibition of HPGDS would be worth investigation once
more inhibitors are available and shown to cross the BBB.
PGD2 receptors:
DP1 - There are no clinical trials with DP1 agonists or antagonists. However, there
are animal studies that show improvement of stroke outcomes by increasing cerebral
blood flow when using DP1 agonist, and a recent study showed potential benefits for diet
induced obesity [60][61]. Notably, DP1 function is well defined in sleep regulation, as DP1
antagonists promote wakefulness while DP1 agonists promote tiredness [62]. Sleep is
dysregulated in older populations and is a risk factor for AD as it is often observed in early
pathology for AD [63]. Potentially DP1 agonists could be explored for its neuroprotective
and sleep promoting properties. However, few DP1 agonists are available and to my
knowledge, none are known to cross the BBB.
DP2 - Much of DP2 therapies come from studying airway and allergic inflammation
in diseases such as asthma and allergic rhinitis [64]. This type of inflammation is attributed
to PGD2 secretion from mast cells along with receptor presence on mast cells. Many DP2
antagonists seem to attenuate the inflammatory response in animal studies for these
diseases. Moreover, many DP2 antagonists are currently in different stages of clinical
trials such as Phase I, Phase II, and Phase III [64]. Since DP2 is expressed in many cell
types, it is surprising that it has not yet been explored in more diseases that involve
chronic inflammation. Timapiprant and Setipiprant were the only two out of 12 DP2
antagonists predicted to cross the BBB. Timapiprant had 12 entries for clinical trials and
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Setipiprant had 5 entries, with both having most entries for diseases of airway
inflammation (Accessed on July 15th, 2022, https://clinicaltrials.gov; Identifiers:
OC000459; ACT-129968). Therefore, my studies focused on Timapiprant because of a
large body of literature showing its efficacy. Studies to predict the BBB penetration was
done using the free webtool Swiss Institute of Bioinfomatics Absorption, Distribution,
Metabolism and Excretion (SwissADME) “Brain Or IntestinaL EstimateD permeation
method” (BOILED‐Egg) [65, 66].
Based on the available literature, I conclude and propose that clinical use of DP2
antagonists and DP1 agonists could offer an alternative to NSAIDs to treat AD.
1.c.2. Polypharmacology for AD: multitarget approach
The only drugs that have been fully approved for AD are not effective enough, as they act
as a band-aid by either reducing glutamate toxicity or increasing acetylcholine levels [67].
Many clinical trials that aim to slow progression for AD focus on only one target of AD
pathology, such as amyloid or tau. However, since AD is non-uniform and there are still
no clear drugs to halt progression of AD, investigators need to be creative in finding novel
strategies [68]. With drug repurposing, finding new drugs can be expedited through the
drug discovery process which has the benefits of good safety profiles, lower costs, and
good efficacy [69]. I propose that multitarget therapeutics would be better candidates by
tackling multiple targets in AD pathology. For example, a therapeutic strategy focused on
aggregation, neuronal death, neuroinflammation, oxidative stress, etc [70]. Additionally,
there is a large body of evidence that patients with dementia have a lower risk of
developing cancer and vice versa [71]. Therefore, anti-cancer medications such as
dibenzoylmethane (DIB), are an attractive option to be explored since there are many

13

drugs that have been developed, and the inverse relationship between cancer and
dementia has been proposed [72]. In AD, calcium ions buildup in the mitochondria of
neurons which leads to high oxidative stress making neurons vulnerable to excitotoxicity
and apoptosis [73]. Dysregulation of calcium signaling can be corrected by agonists to
mitochondrial ATP sensitive potassium channels, such as diazoxide (DZ) [74]. In Chapter
IV, I use DZ and DIB in combination. It is also important to study multiple drug interactions,
because often times older adults have high levels of morbidity and take multiple drugs
with unknown interactions that may lead to adverse events [75].
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2.1. ABSTRACT
We investigated the relevance of the prostaglandin D2 (PGD2) pathway in Alzheimer’s
(AD), because PGD2 is a major prostaglandin in the brain. Thus, its contribution to AD
merits attention, given the known impact of the PGE2 pathway on AD. We used the F344AD transgenic rat model because it exhibits age-dependent and progressive AD
pathology. PGD2 levels in hippocampi of transgenic and wildtype littermates were
significantly higher than PGE2. PGD2 signals through prostaglandin D2 receptor 1 (DP1)
and receptor 2 (DP2). Microglial DP1 receptors were more abundant and neuronal DP2
receptors were fewer in transgenic than in wildtype rats. Expression of lipocalin-type
prostaglandin D synthase, the major brain PGD2 synthase, was the highest among 33
genes involved in the PGD2 and PGE2 pathways. We treated a subset of rats (wildtype
and transgenic males) with timapiprant, a potent highly selective DP2 antagonist in
development for allergic inflammation treatment. Timapiprant significantly mitigated AD
pathology and cognitive deficits in transgenic males. Thus, selective DP2 antagonists
have potential as therapeutics for AD.

2.2. INTRODUCTION
AD is the most common type of dementia, is highly prevalent in the ageing
population, and will become more prevalent as life expectancy continues to rise. AD is a
multifactorial disease, and chronic neuroinflammation is recognized as a critical factor in
its pathogenesis [76]. A major player in inflammation is the COX-mediated signaling
pathway, which is the principal mediator of neuroinflammation [77] [78]. The COX
pathway generates prostaglandins, which are bioactive signaling lipids responsible for
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many processes including inflammation [79]. prostaglandin signaling is implicated in AD,
as some prostaglandins aggravate its pathology while others may remediate it [80]. Based
on data from epidemiological studies, there is a decreased risk of AD in patients taking
NSAIDs, which are inhibitors of the COX pathway [81]. Inhibiting COXs with NSAIDs
could be a promising therapeutic strategy. However, while long-term use of NSAIDs is
associated with a reduced incidence of AD in epidemiologic studies, randomized
controlled trials did not replicate these findings [47]. Moreover, NSAIDs target COX-1
and/or COX-2 enzymes stopping most prostaglandin synthesis. Non-specific inhibition of
prostaglandin synthesis can have a variety of negative side effects,
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prostaglandins have many functions including inflammation, nociception, sleep,
cardiovascular maintenance and reproduction [30]. Accordingly, negative side effects
such as renal failure, heart problems, and stroke were reported for NSAIDs during several
clinical trials [47]. Thus, NSAIDs are not recommended for either primary prevention or
treatment of AD. Based on these concerns, it is important to find new targets further
downstream in the COX-signaling pathway, such as specific prostaglandin signaling that
can be explored for potential therapeutic intervention.
In the current study, we focused on the PGD2 signaling pathway, because PGD2
is the most abundant prostaglandin in the brain and is the one that increases the most
under neuropathological conditions [82, 83]. In the brain, LGDS is the primary synthase
for PGD2 [84]. PGD2 undergoes a nonenzymatic dehydration producing PGJ2 [85].
PGD2 signals through its two antagonistic receptors, DP1 and DP2, the latter also known
as CRTH2 or GPR44. DP1 activation by PGD2 is coupled to the G protein Gs leading
to an increase in cAMP with calcium-flux [31, 86]. DP1 plays a well characterized role in
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sleep function, and in vivo studies show that DP1 modulation is protective in ischemic
and hemorrhagic models of stroke [60, 87, 88]. DP2 receptor activation by PGD2 and
PGJ2, is coupled to the G protein Gi leading to a decrease in cAMP and an increase in
calcium mobilization, both of which can lead to neuronal damage [31]. For example, in
vitro studies show adverse outcomes when treating hippocampal neuronal cultures and
organotypic slices with DP2 agonists [83].
The PGD2 pathway is thoroughly studied in diseases with airway inflammation and
reproduction [38, 64], but its role in AD pathology remains unclear. Investigating the
relevance of the PGD2 signaling pathway in AD is important as it could lead to new
therapeutic strategies to treat neuroinflammation in pre or early stages of AD, and slow
down AD pathology. We investigated the importance of the PGD2 pathway in Tg-AD rats
and their WT littermates. Tg-AD rats express the APPswe (KM670/671NL) and the
PS1ΔE9, both driven by the prion promoter [27]. Tg-AD rats develop AD pathology
including cerebral amyloidosis, tauopathy, gliosis, and neuronal loss, as well as cognitive
deficits, all in a progressive age-dependent manner.
To investigate whether targeting the PGD2 pathway has therapeutic potential for
AD, we treated a subset of rats (WT and Tg-AD males) with timapiprant (also known as
OC000459), a potent and highly selective oral DP2 antagonist. Timapiprant is an indoleacetic acid derivative that potently displaces [3H]PGD2 from human recombinant DP2 (Ki
= 0.013 μM), rat recombinant DP2 (Ki = 0.003 μM), and human native DP2 (Th2 cell
membranes (Ki = 0.004 μM) [89]. Moreover, timapiprant does not interfere with the ligand
binding properties or functional activities of other prostanoid receptors (EP1-4 receptors,
DP1, thromboxane receptor, prostacyclin receptor, and prostaglandin F receptor) [89].
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Timapiprant, which seems to be safe and well tolerated, is under development for oral
treatment of patients with allergic inflammation in diseases such as asthma and allergic
rhinitis [64]. Many DP2 antagonists attenuate the inflammatory response in animal studies
for these diseases. Some demonstrate efficacy in phase II studies in adults with asthma,
and several phase III trials are evaluating the long-term safety and efficacy of these drugs
in adult and pediatric patients with moderate-to-severe asthma [64].
In summary, our studies compared PGD2, PGE2, PGJ2 and thromboxane B2
concentrations, the cellular distribution of the DP1 and DP2 receptors, mRNA profiles for
33 genes involved in the PGD2 and PGE2 pathways in the hippocampus of 11 month old
WT versus Tg-AD rat. We compared these results to Aβ plaque burden, neuronal loss,
microgliosis and their cognitive performance. As far as we know, our studies are the first
to investigate changes in the PGD2 pathway in a rat model of AD, to determine the
relevance of this pathway in AD. We established that PGD2 levels in the hippocampus
are at least 14.5-fold higher than those for PGE2, independently of genotype. In addition,
our data revealed significant differences in DP1 and DP2 receptor levels, respectively in
microglia and neurons of Tg-AD rats compared to controls. Our transcriptome
assessment identified LPGDS as the most abundant mRNA of the 33 genes analyzed.
Notably, we established that the DP2 antagonist timapiprant ameliorated the AD
pathology developed by Tg-AD male rats. Overall, our studies provide novel insights for
the development of therapeutics that target the PGD2 signaling pathway to treat
neuroinflammation in AD.

2.3. MATERIALS AND METHODS
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2.3.1. TgF344-AD transgenic rat model of AD
Fisher transgenic F344-AD (Tg-AD) rats [27] express APPswe) and PS1ΔE9
driven by the prion promoter, at 2.6- and 6.2-fold higher levels respectively, than the
endogenous rat proteins [27]. We purchased the Tg-AD rats and their WT littermates from
Rat Resource and Research Center (RRRC, Columbia, MO) at four weeks of age. The
rats were housed in pairs upon arrival and maintained on a 12h light/dark cycle with food
and water available ad libitum. The Institutional Animal Care and Use Committee at
Hunter College approved all animal procedures.
The Tg-AD rats exhibit a progressive age-dependent AD-like pathology as
depicted in Fig. 2.1A and described in [27], including cognitive deficits, neuronal loss, Aβ
plaque and neurofibrillary tangle burden, as well as gliosis. No differences in pathology
were reported between sexes [27].
2.3.2. Experimental design
A total of 93 rats for the combined female and male studies [WT n = 49 (27 females,
22 males), Tg-AD n = 44 (25 females, 19 males)] across multiple cohorts were used (Fig.
2.2B). For the timapiprant-treated studies, 9 WT and 9 Tg-AD males were used. At seven
months, Tg-AD and WT rats began timapiprant treatment (cat # HY-15342, MCE,
Monmouth Junction, NJ) with 15 mg/kg body weight/day/rat administered orally in rodent
chow (Research Diets Inc. NJ) for four months. Thus, rats were sacrificed at 11 months
of age. Future studies will include timapiprant-treated females.
We evaluated all rats at 11 months of age as described in Fig. 2.2C and 2.2D.
Hippocampal-dependent cognitive deficits were estimated with RAM, which is a passive
behavioral task, and/or the aPAT. Following behavioral testing, the rats were sacrificed,
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the brains rapidly isolated and bisected into hemispheres, and processed for the different
assays as described below and in Fig. 2.2C and 2.2D.
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Figure 2.1 Schematic representation of the experimental design

Figure 2.1 (A) Time line of the progression of the AD pathology
developed by Tg-AD rats. We investigated the AD pathology of Tg-AD
rats at 11 months of age. (B) Rat groups used in the study. (C)
Assessments of the AD pathology developed by the Tg-AD rats at 11
months of age. (D) Timapiprant treatment overview.
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2.3.3. Tissue collection and preparation
At 11-months of age, the rats were anesthetized with an intraperitoneal injection
containing ketamine (100 mg/ kg body weight) and xylazine (10 mg/kg body weight), and
then transcardially perfused with chilled RNAase free PBS. The brain left hemispheres
were micro-dissected into different regions, snap frozen with a CoolRack over dry ice,
and the hippocampal tissue used for mass spectrometry, RNAseq, or western blot
analyses. Whole right brain hemispheres were placed in a 4% paraformaldehyde/PBS
solution for 48 hours at 4°C, followed by cryoprotection with a 30% sucrose/PBS solution
to prevent water-freeze damage, and then flash frozen using 2-methylbutane, and stored
at -80°C until sectioning for IHC.
2.3.4. LC-MS/MS for prostaglandin quantification
Rat hippocampal tissue from 11-month WT (n = 31) and Tg-AD (n = 32) rats were
analyzed by quantitative LC-MS/MS to determine PGD2, PGE2, PGJ2 and thromboxane
B2 (TXB2) concentrations using the standard calibration curves for each compound.
Samples were prepared as previously described [90]. In summary, hippocampal tissues
were homogenized in PBS using a BeadBug microtube homogenizer, then a 10-mg wet
weight equivalent of homogenate was removed and further diluted 1:1 with 1% formic
acid. Deuterated internal standards were added and loaded on a Biotage SLE+ cartridge
and were eluted twice with t-butlymethylether. The eluent was spiked with a trap solution
consisting of 10% glycerol in methanol with 0.01 mg/ml butylated hydroxytoluene.
Samples were dried in a speed vacuum at 35°C, the tubes were washed with hexane and
re-dried. The residue was dissolved in 80:20 water:acetonitrile with butylated
hydroxytoluene and spin filtered with a 0.22 μm Millipore Ultrafree® filter. 30 μl of sample
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were analyzed. Prostaglandin standard curves were spiked into PBS and prepared
identically to the samples. Area ratios were plotted, and unknowns determined using the
slopes.
Prostaglandins were analyzed using a 5500 Q-TRAP hybrid/triple quadrupole
linear ion trap mass spectrometer (Applied Biosystems, Carlsbad, CA) with electrospray
ionization (ESI) in negative mode as previously described [91]. The mass spectrometer
was interfaced to a Shimadzu (Columbia, MD) SIL-20AC XR auto-sampler followed by 2
LC-20AD XR LC pumps. The scheduled MRM transitions were monitored within a 1.5 min
time-window. Optimal instrument parameters were determined by direct infusion of each
analyte. The gradient mobile phase delivered at a flow rate of 0.5 ml/min, consisted of
two solvents, 0.05% acetic acid in water and acetonitrile. The analytes were resolved on
a Betabasic-C18 (100x2 mm, 3 µm) column at 40°C using the Shimadzu column oven.
Data were acquired using Analyst 1.5.1 and analyzed using Multiquant 3.0.1(AB Sciex,
Ontario, Canada).
2.3.5. Immunohistochemistry
Coronal sections were sliced into 30 μm sections using a cryostat (Leica CM3050
S). IHC was restricted to dorsal hippocampal tissue within the following Bregma
coordinates: -3.36 mm to -4.36mm [92]. Sections were mounted on gelatin slides and
immunostained as previously described [90]. Following immunostaining, a mounting
media of VectaShield® with DAPI (Vector Labs # H-1200-10) was used and slides were
stored in the dark at 4°C until imaged. Sections were viewed on a Zeiss Axio Imager M2
with AxioVision software to capture ZVI files of 10x and 20x mosaic images of the whole
hippocampus, and then converted to TIF files. Optical Density (O.D.) was quantified using
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Image J as previously described [93].
Two to three sections (averaged) from each rat were immunostained with either a
combination of anti-DP1 and anti-Iba1 antibodies or anti-DP2 and anti-NeuN antibodies.
Primary and secondary antibodies are listed in Supplemental Table 2.12. For
quantification the following thresholds were used: DP1: mean + 1.5*std, particles
analyzed were in the range: 10-10000, and circularity: 0-1.00; Iba1: mean + 1.5*std,
particles analyzed were in the range: 50-8000, and circularity: 0-1.00; DP2: mean +
1.5*std, particles analyzed were in the range: 10-5000, and circularity: 0-1.00; NeuN:
mean + 1.5*std, particles analyzed were in the range: 10-10000, and circularity: 0-1.00.
Colocalization was analyzed by measuring the overlap of the masks for the two
channels. For DP1 and Iba1 we report the number of microglia co-localized with DP1 per
specific area (nm2). For DP2 and NeuN we report the percentage DP2 and NeuN signals
co-localized within a specific area (nm2). Additionally, Iba1+ ramified, reactive, and
amoeboid microglia phenotypes were analyzed for circularity based on the ImageJ form
factor (FF = 4π x area/perimeter2): ramified (FF < 0.50), reactive (FF: 0.50 to 0.70), and
amoeboid (FF ˃ 0.70) [93].
Astrocytes were immunostained with an anti-GFAP antibody as listed in
Supplemental Table 2.12. For quantification, the following thresholds were used: mean +
1.5*std, particles analyzed were in the range: 30-1000, and circularity 0-1.00.
2.3.6. RNAseq analysis
Hippocampal tissue was used for RNAseq analysis outsourced to the UCLA
Technology Center for Genomics & Bioinformatics services. Samples from five male WT
and five male Tg-AD rats were compared, and the same for female rats. Briefly, total RNA
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was isolated from the hippocampal tissue using the RNeasy Mini Kit from Qiagen. The
integrity of total RNA was examined by the Agilent 4200 TapeStation System. Libraries
for RNAseq were constructed with the Kapa Stranded mRNA Kit (Roche, cat. KK8421) to
generate strand-specific RNAseq libraries, which were amplified, and sequencing was
performed with the HiSeq3000 sequencer. Gene expression data were normalized as
reads per million (RPM) using the Trimmed Mean of M-values (TMM) method.
Differentially expressed genes between WT and Tg-AD rats for each sex were determined
using the edgeR program [94]. RPMs were analyzed for fold-change, p values, and false
discovery rate (FDR) for each gene (Supplemental Table 2.8).
2.3.7. Western blot analysis
Hippocampal tissue (20-25 mg) was homogenized in TBS for 90 sec at 25°C with
the Bedbug Microtube Homogenizer (3,400 rpm, Model D1030, Benchmark Scientific).
The supernatant was stored for 16 h at -80°C, followed by centrifugation at 14,000 rpm
for 20 min at 4°C. The supernatant was filtered using biomasher homogenizer tubes (#09A10-050, OMNI International). Samples were stored at -80°C until use. Protein
concentration was determined with the BCA assay (Pierce Biotechnology), followed by
normalization. Either 30 μg (for DP2, PPARγ, LPGDS, Sox-2, COX-2) or 50 μg of protein
(for DP1) from each sample were run on 4-12% SDS gels and transferred to nitrocellulose
membranes with the iBlot® dry blotting system (Life Technologies) for 7 min. Membranes
were blocked with SuperBlock (#37535, ThermoFisher), and hybridized with various
primary antibodies followed by HRP-conjugated secondary antibodies (Supplemental
Table 2.12), prior to developing with an enhanced chemiluminescence (ECL) substrate
(SuperSignal™ West Pico PLUS, ThermoFisher #34580), and detected on a BX810
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autoradiography film (Midwest Scientific). ImageJ software (Rasband, W.S., ImageJ, U.
S. National Institutes of Health, Bethesda, Maryland, USA, https://imagej.nih.gov/ij/,
1997-2018) was used for semi-quantification by densitometry of the respective bands.
Loading controls used were GAPDH, tubulin, or β-actin depending on their molecular
weights to avoid overlapping with the other proteins studied.
2.3.8. Cognitive behavior assessment with the passive radial 8-arm maze
This variant of RAM is a passive task that uses
positive reinforcement (food) to assess spatial
working memory. This RAM is classified as working
memory because only short-term memory is used,
and memory of previous trial baits will not aid the rat
in later trials as all baits are used and replenished
after each trial. This hippocampal dependent task
uses spatial cues in the test room. The maze is
divided into eight arms with a bait of food (Ensure®
Food Supplement) at the end of each arm in a

Fig 2.2 RAM was used to access
short term spatial working
memory in the Tg-AD rats. This
behavioral task is hippocampal
dependent.

submerged food cup. Prior to training, rats were food
(created with BioRender.com).

deprived to 85% of their ad libitum body weight and
received six shaping trials across two days. For training, the rats were tested four times
across two days. The rats begun the training confined to the center of the arena with an
opaque covering. Once the opaque covering was removed, the rat was free to start the
trial to collect all eight baits. Entrances were recorded after the rat crossed halfway across
the arm towards the bait. When the rat returned to a bait that was previously consumed
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this was deemed as an error. Animals were required to collect all eight baits for the trial
to end, and if the trial exceeded 25 min, the trial was not included in the analysis. After
each trial, the maze was shifted at 90° and cleaned with a 70% ethanol solution to prevent
internal maze cues being used. To prevent the rats using their sense of smell to find baits,
the maze room had ample food placed throughout the maze room. Data of all fully
completed training trials were analyzed.
2.3.9. Cognitive behavior assessment with active place avoidance task
This variant of aPAT is an active task
that uses negative reinforcement (shock) to
access spatial learning (Fig 2.3 [95]). This
aPAT is classified as reference memory
because long-term spatial learning is used as
the rats experience repeated trials with a fixed
shock quadrant, so referencing previous trials
will aid in better performance. The task
challenges the rat to avoid a fixed quadrant of

Fig 2.3 aPAT was used to access
spatial learning with six consecutive
trials. Over the six trials the rat will
learn to actively avoid the shock zone.
Adapted from [95]

the arena as the arena rotates at one revolution
per minute. A computer-controlled system was used for aPAT (Bio-Signal Group, Acton,
MA). The arena used for this task was enclosed with a transparent plastic wall that was
fixed to the arena. An overhead camera (Tracker, Bio-Signal Group) was calibrated to the
white hue of the rats and tracked the rat’s movement. This hippocampal-dependent task
used spatial cues in the test room. The rotating arena forced the rat into the fixed
quadrant. After the system detected that the rat was in the fixed quadrant for 1.5s, the
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system delivered a pulse shock of 0.2 milliamperes throughout the arena every 1.5s,
giving the rat a foot shock and subsequent foot shocks until it left the fixed quadrant. The
rotating arena forced the rat to actively avoid the fixed quadrant, otherwise it would
receive a shock. This hippocampal-dependent task uses spatial cues to help the rat
navigate within the spatial environment. Before training, rats were habituated to the
rotating arena for 10 min without a shock. For training, the rats received six 10-min trials
with 10-min breaks in their home cage between every trial. To access retention, on the
next day the rats received a 10-min trial without a shock zone. The system software
recorded data for all trials, and all data were exported to .tbl files and analyzed offline
(TrackAnalysis, Bio-Signal Group).
2.3.10. Statistics
All data are represented as the mean ± SEM. Statistical analyses were performed
with GraphPad Prism 9 (GraphPad Software, San Diego, CA). All p values, SEMs and tstatistics are shown on graphs and/or in supplemental tables. Welch’s unpaired one-tailed
t test was used to compare means between the two groups (WT and Tg-AD) for
prostaglandin (Fig. 2.4), IHC (Fig. 2.5-2.6, Supplemental Tables 2.1-2.7), WB (Fig. 2.8,
Supplemental Table 2.7), RAM (Fig. 2.9A-D), and the two groups (TGNT, Tg-AD nontreated, and TGTR, Tg-AD timapiprant-treated males, Fig. 10B-10F). Multiple unpaired ttest was used for RNAseq (Fig. 2.7, Supplemental Table 2.8) for the 33 prostaglandin
genes with an FDR set to 1% using the two-stage step-up method (Benjamini, Krieger,
and Yekutieli). Multi-factor comparisons for aPAT (Fig. 2F-2I and Fig. 2.10A) were
performed using a two-way repeated measure analysis of variance (ANOVA), followed by
a post hoc (Sidak’s) to access differences across individual training trials or conditions.
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2.4. Results
2.4.1. PGD2 is the most abundant prostaglandin in the hippocampus of WT and TgAD rats
Rat hippocampal tissue from 11-month WT (n = 31) and Tg-AD (n = 32) rats was
analyzed to determine PGD2, PGE2, PGJ2 and TXB2 concentrations. Quantitative levels
of the four prostanoids ranged from 0.7 to 110.2 pg/mg wet tissue. The levels measured
in the order of abundance were PGD2, TXB2, PGE2, and PGJ2, at 49.1 ± 4.1, 17.0 ± 1.5,
3.4 ± 0.4, and 2.0 ± 0.2 pg/mg wet tissue for WT rats (Fig. 2.4A-D). Prostanoid levels
were similar in Tg-AD and WT littermate. Quantitative amounts of the four prostanoids in
Tg-AD rats measured in the order of abundance were PGD2, TxB2, PGE2, and PGJ2, at
43.2 ± 4.7, 14.6 ± 1.5, 2.4 ± 0.3, and 1.4 ± 0.1 pg/mg wet tissue (Fig. 2A-D). In seven TgAD rats, PGJ2 was not detectable. The latter is produced from PGD2 by non-enzymatic
dehydration and its formation in vivo remains controversial [96, 97]. All of these values
are in accordance with those previously reported for Sprague-Dawley male rat brain
cortical tissue at postnatal day 16–18, measured by quantitative UPLC–MS/MS (Shaik et
al., 2014; Shaik, 2013). Under normal conditions, quantitative amounts of PGD2, PGJ2,
and PGE2, measured in the order of abundance were 123.7, 12.3, and 4.5 pg/mg wet
tissue, or 351, 36.9, and 12.8 pmol/g wet tissue [98, 99]. The differences between the
latter study and ours can be accounted for by the prostaglandin levels being quantified in
different rat strains, at different ages and in different brain regions.
Out of the four prostanoids measured, PGD2 was by far the most abundant in the
hippocampal tissue, as reflected in the pie graphs shown in Fig. 2E-F. These graphs
represent the proportion of each of the four prostanoids relative to their total sum. For
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example, it is clear that PGD2 levels are 14.5-fold and 17.5-fold higher than PGE2 in WT
and Tg-AD rats, respectively (Fig. 2.4E-F). PGD2 levels represent 68.8% and 70.1%
relative to total, while PGE2 levels represent 4.7% and 4.0% relative to total in WT and
Tg-AD rats, respectively.
The specific chromatographic profiles of calibration standards for each prostanoid
is depicted in Fig. 2G, showing that the four prostanoids derived from arachidonic acid
can be quantified reliably in rat hippocampal tissue using LC-MS/MS analysis. Under our
experimental conditions, the elution sequence was identified as TxB2, PGE2, PGD2, and
PGJ2.
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Figure 2.4 Tg-AD rats have higher levels of microglia and DP1/microglia colocalization in the dorsal hippocampus than WT rats.

Fig. 2.4 Concentrations of prostanoids (A) PGD2, (B) PGE2, (C) PGJ2, and (D) TXB2,
measured by LC-MS/MS in whole left hippocampal tissue (combined ventral and dorsal) from
11-month WT (n = 31) and Tg-AD (n = 32) rats. Prostanoid levels were equivalent in Tg-AD
and WT littermates, except for PGJ2 that were less (t = 2.668, p = 0.005). Significance
estimated with a two-tailed Welch’s t test. (E-F) Pie graphs represent the proportion of each
of the four prostanoids relative to their total sum, in (E) WT and (F) Tg-AD rats. PGD2 is the
most abundant prostanoid in both WT and Tg-AD rats. (G) Chromatographic profiles depicting
the separation of the four prostanoids using LC-MS/MS as explained under materials and
methods.
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2.4.2. Tg-AD rats have enhanced microglia and DP1/microglia co-localization levels
in the hippocampus
We assessed DP1 and microglia levels in the hippocampus of WT and Tg-AD rats at 11
months of age [Fig. 2.5A: DP1, red; microglia, green; DP1/microglia co-localization,
yellowish (indicated by single white arrows)]. It is clear that DP1 is detected in the four
discrete hippocampal regions (SB, CA1, CA3, and DG) in WT and Tg-AD rats (Fig. 2.5A).
For DP1 levels, there were no significant differences between WT and Tg-AD rats,
considering the four hippocampal regions individually (Fig. 2.5B, left graph for DG only
and Supplemental Table 2.1 for all). A different situation was observed for microglia, as
Tg-AD rats had significantly more microglia than WT rats, in all hippocampal regions
except for CA3 (Supplemental Table 2.2). For example, Tg-AD rats had more microglia
(1.4 fold, t = 3.15, p = 0.003) in the DG hilar (HL) subregion than their WT littermates [Fig.
2.5B, middle graph for DG (HL) only)].
It is evident that DP1 is co-localized with microglia in all four hippocampal regions
(Fig. 2.5A), shown at higher magnification for the DG (HL) (Fig. 2.5A, bottom panels,
indicated by single white arrows). Tg-AD rats had significantly higher levels (1.5 fold, t =
2.99, p = 0.005) of DP1/microglia co-localization than their WT littermates, only in the DG
(HL) region [Fig. 2.5B, right graph for DG (HL) only, and Supplemental Table 2.3 for all].
Microglia have a remarkable variety of morphologies associated with their specific
functions, and can be divided into three phenotypes according to their cell body circularity:
ramified, reactive and amoeboid [100] (Fig. 2.5C). The majority of microglia are ramified
with long slender processes and play a role in surveillance. Reactive microglia, present
in intermediate numbers, exhibit shorter processes and a larger soma than ramified
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microglia, and are in an activated state producing immune modulators. Finally, amoeboid
microglia are the fewest, have the largest soma and fewest processes, and perform
phagocytosis.
Notably, when compared to WT controls, Tg-AD rats showed a shift from a
neuroprotective state typical of ramified microglia, to more of a neurotoxic and overactive
state attributable to amoeboid microglia. In the hippocampal DG (HL), there are significant
less ramified microglia (14.5 % less, t = 2.32, p = 0.02) with a concomitant increase in
reactive (1.6 fold more, t = 2.52, p = 0.01) and amoeboid (1.8 fold more, t = 1.89, p =
0.04) microglia in Tg-AD rats compared with WT controls (Fig. 2.5D).
Co-localization of DP1 with each microglia phenotype in the hippocampal DG (HL) was
significantly higher in Tg-AD rats than in WT littermates (Fig. 2.5E). Accordingly,
compared to WT controls, the Tg-AD rats had 1.3 fold (t = 2.19, p = 0.02), 2.5 fold (t =
3.53, p = 0.002), and 3.2 fold (t = 3.08, p = 0.003) higher DP1 co-localization with ramified,
reactive and amoeboid microglia, respectively.
No significant differences between WT and Tg-AD rats were detected for astrocyte
levels by IHC analysis at 11 months of age in all hippocampal regions (GFAP levels,
Supplemental Table 2.4).
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Figure 2.5 A: Tg-AD rats have higher levels of microglia and DP1/microglia colocalization in the dorsal hippocampus than WT rats.

Fig. 2.5 (A) DP1 (red), microglia (green, Iba1 antibody), and DP1/microglia co-localization
(yellow) IHC analysis of the right dorsal hippocampus of WT (left column, n = 12) and Tg-AD
(right column, n = 11). Large panels: 10x magnification, 500 μm scale bars. Small (bottom)
panels: 20X magnification of the small white boxes depicted in the larger panels, 50 μm scale
bars. White arrows indicate: full, DP1/microglia co-localization; single head, ramified microglia,
double head, amoeboid microglia. For DP1 levels, there were no significant differences
between WT and Tg-AD rats across all hippocampal regions
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Figure 2.5 B-E: Tg-AD rats have higher levels of microglia and DP1/microglia colocalization in the dorsal hippocampus than WT rats

Fig. 2.5 B-E (B, left graph for DG and Supplemental Table 1). Tg-AD rats had significantly more microglia than WT
rats, in all hippocampal regions except for CA3 (B, middle graph for DG and Supplemental Table 2). Tg-AD rats
also had significantly higher levels (1.5 fold) of DP1/microglia co-localization than their WT littermates, only in the
DG (HL) region (B, right graph for DG only and Supplemental Table 3). (C) The three microglia (Iba1+) phenotypes
based on circularity (form factor) as explained under material and methods. (D) Microglia phenotypes as % of total
counts at DG (HL). Each pie slice represents the proportion of each phenotype relative to the total sum, in WT (left)
and Tg-AD (right) rats. Tg-AD rats had significantly fewer ramified, but more reactive and almost double amoeboid
microglia than controls. (E) Co-localization of DP1 with each microglia phenotype in the hippocampal DG (HL) was
significantly higher in Tg-AD rats than in WT littermates. Significance (p values shown on graphs) estimated by a
one-tailed Welch’s t test.
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2.4.3. Tg-AD rats display neuronal and DP2 receptor loss in the hippocampus
Neuronal density across hippocampal regions (SB, CA1, and CA3 pyramidal cell layers,
and DG granular cell layer) were assessed with NeuN (green) to quantify mature neurons
(Fig. 2.6A-D and Supplemental Fig. 2.1). Similar to what was reported in the original study
for Tg-AD rats at 16 and 26 months of age [27], we observed a significant neuronal loss
(NeuN signal) though earlier, at 11 months of age. We detected neuronal loss in Tg-AD
compared to WT rats, only in the GCL and CA3c pyramidal cell layer of DG (44.2% less,
t = 4.75, p < 0.0001 for GC, and 21.4% less, t = 2.07, p = 0.03 for CA3c) (Fig. 2.6A-D, left
graphs). It is clear that the thickness of the GCL is greater in WT than in Tg-AD rats,
shown at higher magnification (Fig. 2.6A, bottom panels indicated by white double head
arrows). Neuronal levels analyzed across all other hippocampal regions revealed no
changes in Tg-AD compared to WT rats (Supplemental Table 2.5).
A similar trend was detected for DP2 receptor levels (red) at the GCL only. Tg-AD
rats exhibited significantly fewer DP2 receptors in GCL than the WT controls (34.4% less,
t = 7.25, p < 0.0001 for GCL) (Fig. 2.6A and C, and Supplemental Table 2.6). In all other
hippocampal regions, there were no differences in DP2 levels between WT and TG-AD
rats, except in the CA1 region, where DP2 levels were 1.3 fold higher in Tg-AD than in
WT controls (t = 3.36, p = 0.002 and Supplemental Table 2.6). The observed DP2
increase in the CA1 region of Tg-AD rats is likely due to the presence of Aβ plaques.
It is clear that at least 50% of DP2 is co-localized with neurons, as shown in Fig.
2.6A (yellow). For this reason, DP2 receptor and neuronal co-localization was not
significantly different between WT and Tg-AD rats at all hippocampal regions. This finding
supports that at least 50% of NeuN and DP2 signals are co-localized, and that their
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decrease in Tg-AD compared to WT, follows the same trend (Supplemental Table 2.7).
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Figure 2.6A: Tg-AD rats display DP2 and neuronal losses in the dorsal
hippocampus.

Fig. 2.6 A: Tg-AD rats display DP2 and neuronal losses in the dorsal
hippocampus. (A) DP2 (red), neurons (green, NeuN antibody), and
DP2/neuronal co-localization (yellow) IHC analysis of the right dorsal
hippocampus of WT (left column, n = 12) and Tg-AD (right column, n = 11).
Large panels: 10x magnification, 500μm scale bars. Small (bottom) panels:
20X magnification of the small white boxes at the GCL depicted in the larger
panels, 50μm scale bars. It is clear that the thickness of the GCL is greater in
WT than in Tg-AD rats (white double head arrows).
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Figure 2.6 B-D: Tg-AD rats display DP2 and neuronal losses in the dorsal
hippocampus.

Fig 2.6 (B – D, left graphs) Neuronal loss detected only in the DG (B), at the GCL (C) and
CA3c (D) of Tg-AD compared to WT rats. Neuronal density analyzed across all other
hippocampal regions revealed no changes in Tg-AD compared to WT rats (Supplemental
Table 2.5). (B – D, right graphs) DP2 loss detected only at the GCL (C) but not at the other
hippocampal locations (B and D, and Supplemental Table 2.6) of Tg-AD compared to WT
rats. Significance (p values shown on graphs) estimated by a one-tailed Welch’s t test.
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2.4.4. Lipocalin prostaglandin D2 synthase (LPGDS) mRNA levels are the highest
among 33 genes evaluated by RNAseq in the hippocampus of WT and Tg-AD rats
We assessed the mRNA levels for 33 genes involved in the PGD2 and PGE2 pathways
in hippocampal tissue from WT and Tg-AD male (5 of each genotype) and female (5 of
each genotype) rats. The RNAseq analysis reports output measures as RPM, as well as
FDR and p values (Supplemental Table 2.8). In addition, the mRNA levels (mean RPMs)
for 21 of those genes are displayed as pie graphs, in which a slice of each pie is
proportional to the total for a specific functional group of genes (Fig. 2.7). The functional
groups within the Prostaglandin pathway are depicted in Fig. 2.7A. The numbers shown
on the pie graphs (Fig. 2.7B-F) represent the RPMs from WT females only, as there were
no significant genotype (WT vs Tg-AD) or sex (male vs female) differences in the
expression levels for most of these genes (Supplemental Table 2.8).
Overall, the data revealed that mRNA transcript levels were the highest for
LPGDS, the PGD2 synthase in the brain (RPM = 282.7, Fig. 2.7C). This is consistent with
PGD2 being the most abundant prostanoid of the four that we measured in hippocampal
tissue (as much as 70% of the total, Fig. 2.7E and F). HPGDS, the other PGD2 synthase
that is mainly detected in microglia [35], was minimally expressed (RPM = 1.13, Fig.
2.7C). There were three PGE2 synthases detected by RNAseq, and their mean RPMs
were in descending order, 165.8 (PGES-3), 46.5 (PGES-2), and 16.5 (PGES-3-like1) (Fig.
2.7C).
Evaluation of four genes involved in prostaglandin biosynthesis and metabolism
(Fig. 2.7B), showed that prostaglandin reductase-2 (pTGR-2), which metabolizes
prostaglandins, exhibited the highest expression (RPM = 70.6). The remaining three
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genes followed in descending order, COX-2 (RPM = 23.6), COX-1 (RPM = 16.6) and
phospholipase A2 (RPM = 7.4).
In the rat hippocampal tissue, the mRNA levels (RPM) for PGD2 receptors were,
in descending order, as follows (Fig. 2.7D): DP1 (rat, orthologous to human DP1, 0.43),
DP2 (0.41), and DP1 (0.09). The rat genome has two DP1 copies (genes: PTGDR, ID:
63889 and PTGDRL, ID: 498475). The protein alignments are highly similar (354/357
residues, 99% homology, NCBI groups the two in an identical protein group), differing
only on their location on chromosome 15. RPMs for PPARγ, a putative PGJ2 receptor,
were = 0.24. Notably, PPARγ activators were expressed at higher levels than the receptor
itself (Fig. 2.7E): co-activator related 1 (30.3), co-activator 1α (20.2), and co-activator 1β
(6.6). The receptors for PGE2 showed the highest RPM levels (Fig. 2.7F) listed in
descending order: EP1 (5.51), EP3 (1.54), EP2 (1.14), and EP4 (0.39).
The SRY-box transcription factor 2 (Sox-2) gene is a transcription factor best
known as a reprogramming factor necessary for generating induced pluripotent stem cells
[101]. Sox-2 is also required for proliferation and differentiation of oligodendrocytes during
postnatal brain myelination and CNS remyelination [102]. In addition, Sox-2 is a negative
regulator of myelination by Schwann cells, and its levels are controlled by LPGDS in PNS
injured nerves [23, 103]. We found that Sox-2 expression levels in the hippocampal tissue
were quite high (79.4 RPM, Fig. 2.7E), being the third highest expressed gene in our list,
after LPGDS and PGES-3 (Supplemental Table 8). Moreover, Sox-2 was significantly
downregulated in male Tg-AD rats compared to their WT littermates (22.2 % less, p =
0.011, Supplemental Table 8). The significance of these data will be addressed in the
discussion.

42

RNAseq pie graphs for WT and Tg-AD male and female rats are shown in
Supplemental Fig. 2.2-2.6. In addition, western blot analyses for six proteins involved in
the PGD2 pathway, i.e. receptors DP1, DP2, and PPARγ, the synthase LPGDS, as well
as COX-2 and Sox-2, are shown in Supplemental Fig. 2.7. The data indicate no changes
in the levels of these protein in hippocampal tissue from WT and Tg-AD male (n = 3 for
each genotype) and female (n = 3 for each genotype) rats (Supplemental Table 2.9). The
whole image of the western blots for DP1, DP2 and LPGDS is shown in Supplemental
Fig. 2.10C.
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Figure 2.7: Lipocalin prostaglandin D2 synthase (L-PGDS) mRNA levels are the
highest among 21 genes evaluated by RNAseq in the hippocampus of WT and TgAD rats.

Fig. 2.7. (A) The functional groups analyzed within the PG pathway. (B – F) mRNA levels for 21
genes involved in the PGD2 and PGE2 pathways were determined by RNAseq in whole left
hippocampal tissue (combined ventral and dorsal) from 11-month WT and Tg-AD male (5 of each
genotype) and female (5 of each genotype) rats. The mRNA levels (mean RPMs, WT females only)
are displayed as pie graphs, in which each slice is proportional to the total for a specific functional
group of genes. The mRNA transcript level was the highest for L-PGDS, the PGD2 synthase in the
brain (C). Most of the mRNA levels of the 21 genes were not significantly different between Tg-AD
rats and WT littermates, except for example the transcription factor Sox-2, which was significantly
downregulated in male Tg-AD rats compared to their WT littermates. Additional details are in the
text and Supplemental Table 2.8.
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2.4.5. Tg-AD rats show enhanced FL-APP and Aβ peptide levels as well as Aβ
plaques in the hippocampus
The original study by Cohen et al reported that Tg-AD rats express 2.6-fold higher
levels of human full-length APP than their WT littermates, assessed by western blot
analysis of the brain [27]. Full length APP (FL-APP) was detected with the mouse
monoclonal antibody 22C11, which reacts with human and rat, as well as other species
(manufacturer’s specifications). In our studies using the same antibody, it is clear that the
levels of FL-APP are 5.6 fold higher in the hippocampal tissue of Tg-AD than WT rats
(Fig. 2.8A, top panels labeled with FL-APP, and Fig. 2.8B, left graph, combined males
and females, t = 7.23, p < 0.001). This trend was observed in males (n = 3 for each
genotype) and females (n = 3 for each genotype), and the values were normalized for
actin (Fig. 2.8A, second panels). The higher levels of FL-APP detected in our analysis
compared to the original Cohen et al study, could be explained by our studies evaluating
hippocampal tissue while whole brain tissue was used in the original Cohen et al study
[27].
We also assessed Aβ levels in the same samples of rat hippocampal tissue with
the mouse monoclonal antibody 6E10, which has a 3-fold higher affinity for human APP
and Aβ compared to rat (manufacturer’s specifications). Aβ peptides were detected in
male and female Tg-AD rats but not in the WT littermates, as shown in Fig. 2.8A [third
panels labeled with Aβ (6E10)], and semi-quantified in Fig. 2.8B (right graph, combined
males and females, t = 3.62, p = 0.008). The whole images of the western blots for FLAPP and Aβ are shown in Supplemental Fig. 2.10D.
The presence of Aβ plaques in all 11-month Tg-AD rats was confirmed by IHC
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analysis with the mouse monoclonal antibody 4G8, as shown for a female rat in Fig. 2.8C,
right panel. A WT female rat is included for comparison (Fig. 2.8C, left panel).
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Figure 2.8: Tg-AD rats show enhanced FL-APP and Aβ peptide levels as well as
A plaques in the hippocampus

Fig. 2.8. (A) FL-APP (top panels) and A levels (third panels from the top) were assessed by western blot analysis
in whole left hippocampal (combined ventral and dorsal) homogenates from 11-month WT and Tg-AD male (M,
3 of each genotype) and female (F, 3 of each genotype) rats. Actin (second panels from the top) and GAPDH
(bottom panels) detection served as the respective loading controls. (B) FL-APP and A levels semi-quantified
by densitometry. Data represent the percentage of the pixel ratio for FL-APP and A over the respective loading
controls for Tg-AD compared to WT (represented as a value of one). Values are means  SEM from 6 rats per
genotype (males and females combined). Significance (p values shown on graphs) estimated by a one-tailed
Welch’s t test. (C) Immunohistochemistry for A plaque load for WT (left panel) and Tg-AD (right panel) rats is
shown at 10x magnification, scale bars = 500μm. All Tg-AD rats used in this study exhibited Aβ plaques, but not
their WT littermates.
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2.4.6. Tg-AD rats exhibit impaired spatial learning and memory
In the original studies with the Tg-AD rats, cognitive behavior was assessed at 6,
15 and 24 months of age [27]. Most of the significant changes between WT and Tg-AD
rats were detected at 15 and 24 months, but not at 6 months of age [27]. To shorten the
experimental timeline, we evaluated the WT and Tg-AD rats at an earlier age, i.e. at 11
months. We evaluated cognitive impairment with two hippocampal-dependent tasks to
measure short-term learning/memory and navigation: RAM, which is a passive behavioral
task, and aPAT. Since in the original studies no sex differences were reported [27], males
and females were combined for our analyses.
In our RAM studies, we wanted to assess total errors made, baits collected until
error, and working memory. Two forms of working memory were assessed, a light working
memory load for baits 1-4, and a heavy (challenging) working memory load for baits 5-8
(Fig. 2.9). For RAM the rat groups were WT (10 females, 4 males) and Tg-AD (5 females
and 4 males). We found that Tg-AD rats had a behavioral deficit in outputs for baits
collected until error (Fig. 2.9A, t = 2.65, p = 0.01) and in light working memory load (Fig.
2.9B, t = 2.75, p = 0.01). We found no differences in the more difficult measures such as
heavy working memory load (Fig. 2.9C; t = 1.26, p = 0.11) and total errors (Fig. 2.9D, t =
0.48, p = 0.32). These findings show a working memory impairment in the early and less
challenging part of the task for the Tg-AD rats compared to controls.
In the aPAT analysis, we used a separate cohort of rats. In aPAT, the rat groups
were WT (7 females, 7 males) and Tg-AD (8 females, 6 males). We found a significant
deficit in spatial reference memory during training for the Tg-AD rats in all of the reported
measures: latency to 1st entrance (Fig. 2.9F, F(1,26) = 5.73, p = 0.02), latency to 2nd
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entrance (Fig. 2.9G, F(1,26)=5.70, p = 0.02), maximum time avoidance (Fig. 2.9H,
F(1,26)=4.74, p = 0.04) and entrances (Fig. 2.9I, F(1,26) = 4.78, p = 0.04). Significant
post hoc differences were observed at trial 2 during the early acquisition (EA) phase in
latency to 2nd entrance (Fig. 2.9G, t = 3.05, p = 0.03), and in the number of entrances
(Fig. 2.9I, t = 2.81, p = 0.03). Representative track tracings for trial 2 are shown for WT
and Tg-AD female rats (Fig. 2.9J).
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Figure 2.9 A-E: Tg-AD rats exhibit impaired spatial learning and memory at 11
months of age.

Fig. 2.9. Results with RAM show Tg-AD rats (n = 9) commit significantly more errors
vs WT rats (n = 14) when analyzed (A) for baits collected until first error, and (B) for
working memory errors committed during collection of bait numbers 1-4 (light memory
load). (C) No significant differences were observed between conditions with a heavy
(challenging) working memory load (collection of baits 5-8), or (D) for total errors
committed collecting all 8 baits. Significance estimated with a one-tailed Welch’s t
test, and p values are shown above bar graphs. (E) RAM with the arms labelled 1 –
8 (created with BioRender.com).
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Figure 2.9 F-J: Tg-AD rats exhibit impaired spatial learning and memory at 11
months of age.

Fig. 2.9 (F) Analysis of latency to first entrance shows Tg-AD rats exhibiting significantly shorter
latencies. (G) Latency to second entrance shows a significant post-hoc difference on trial 2, *p = 0.03.
(H) Maximum time to avoid shows Tg-AD rats exhibiting significantly shorter maximum avoidance
latencies. (I) Number of entrances shows a significant post-hoc difference on trial 2, *p = 0.03. (J)
Representative track tracings for trial 2 shown for WT and Tg-AD female rats. Significance estimated
by a two-way repeated measure ANOVA with Sidak’s post hoc for multiple comparisons.
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2.4.7. Timapiprant improves spatial learning and mitigates plaque burden,
neuronal loss and microgliosis in Tg-AD rats
We used the hippocampal-dependent active place avoidance task to assess shortterm working memory performance on 11-month old Tg-AD non-treated (TGNT) and TgAD timapiprant-treated (TGTR) male rats, and the equivalent WT male littermates. The
measurements latency to first and second entrance into the shock zone for TGTR vs
TGNT revealed overall significant effects for treatment (1st entrance: Fig. 2.9A, Sup Table
2.10 F (1, 16) = 13.87, p = 0.002) (2nd entrance: Sup. Table. 2.11 F (1, 16) = 5.373, p =
0.03) and of training (1st entrance: Fig. 2.10A, Sup. Table 2.10, F (5, 80) = 2.93, p = 0.02)
(2nd entrance: Sup. Table 2.11, F (5, 80) = 6.307, p <0.001). Significant post hoc
differences were observed at trial 5 during the asymptotic performance (AP) phase in
latency to 1st entrance (Fig. 2.10A, t = 3.15, p = 0.01) between TGTR and TGNT rats. No
differences were detected between WTNT and WTTR males (1st entrance: Sup. Table
2.10 F (1, 16) = 1.04, p = 0.32) (2nd entrance: Sup. Table 2.11 F (1, 16) =0.1046, p =0.75),
nor between WTNT and TGTR (1st entrance: Sup. Table 2.10 F (1, 16) = 0.88, p = 0.36)
(2nd entrance: Sup. Table 2.11 F (1, 16) =2.051, p =0.17), showing the beneficial effects
of timapiprant-treatment only under pathological conditions.
We compared Aβ plaque burden in the hippocampal DG hilar subregion between
TGTR and TGNT rats and found that timapiprant significantly mitigated Aβ plaque load
(Fig. 2.10B, t = 3.55, p = 0.001, and Fig. 2.10G). Similarly, timapiprant alleviated neuronal
loss in the GCL subregion (Fig. 2.10C, t = 2.56, p = 0.01) and microgliosis in the hilar
subregion (Fig. 2.10D, p < 0.001) for TGTR compared to TGNT male rats. DP1 receptor
levels were decreased in the DG hilar subregion of TGTR compared to TGNT male rats
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(Fig. 2.10E, t = 2.78, p = 0.007), but not those of the DP2 receptor in the GCL (Fig. 2.10F,
t = 1.29, p = 0.11).
The levels of FL-APP and Aβ were similar in TGNT and TGTR males when
assessed by western blot analysis (Fig. 2.10H, t = 2.34, p = 0.50). The discrepancy on
the A level comparison between TGNT and TGTR rats is explained by the western blot
analysis (Fig. 2.10H) with the whole hippocampus, while the IHC analysis (Fig. 2.10B and
G) includes Aβ plaques only in the hippocampal DG hilar subregion. The whole images
of the western blots for FL-APP and Aβ are shown in Supplemental Fig. 2.9.
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Fig. 2.10 A-G Timapiprant mitigates AD pathology

Fig. 2.10 A-G. Tg-AD timapiprant-treated (TGTR, n = 9) compared to Tg-AD non-treated (TGNT, n = 9) male rats
perform significantly better in latency to first entrance during training (A, p = 0.002) with a significant post-hoc difference
on trial 5, experience lower plaque burden (B, p = 0.001), higher neuronal levels (C, p = 0.01), and lower microglia
levels (D, p < 0.001) in the DG hilar subregion of the hippocampus. DP1 and DP2 receptor levels were decreased (E,
p = 0.007) and unchanged (F, p = 0.11), respectively, in the same hippocampal subregion of TGTR vs TGNT male
rats. Unpaired one-tail t-tests with Welch’s corrections were used for statistical analysis. EA - early acquisition; AP –
asymptotic performance; T**, training effect; Tr*** = timapiprant-treatment effect; (*p < 0.05; ** p < 0.01; *** p < 0.001).
(G) Immunohistochemistry for A plaque load for TGNT (left panel) and TGTR (right panel) rats is shown at 10x
magnification, scale bars = 500μm.
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Fig. 2.10 H. Timapiprant mitigates AD pathology

Fig. 2.10H. (H) FL-APP (top panels) and A levels (third panels from the top) were assessed by western blot analysis in whole left
hippocampal (combined ventral and dorsal) homogenates from 11-month WT and Tg-AD (TG) not treated (NT) and timapiprant treat
(TR) male rats. Actin (second and fourth panels from the top) detection served as loading control. Graphs show FL-APP (left) and A
(right) levels semi-quantified by densitometry. Data represent the percentage of the pixel ratio for FL-APP and A over the respective
loading controls for TGTR compared to TGNT (represented as a value of one). All graphed data (C-F, and H except for A/actin)
represent a ratio of the Tg-AD over their WT controls. Values are means  SEM. Significance (p values shown on graphs) estimated
by a one-tailed Welch’s t test.
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2.5. DISCUSSION
There is still much to learn about the profile and role of prostaglandins in AD
pathology. We focused on the PGD2 pathway, because PGD2 is the most abundant
prostaglandin in the brain, and its contribution to AD merits more attention. Much more is
known about the relation between the PGE2 pathway and AD [104]. Investigating the
relevance of the PGD2 pathway to AD could discover potential biomarkers and/or
therapeutic targets for treating this devastating disease.
We investigated the PGD2 pathway in Tg-AD rats at 11 months of age, because it
is midway between the ages at which these rats present mild (at 6 months of age) and
robust (at 16 months of age) AD pathology, as reported in the original study [27].
Understanding pre- and/or early-stages of AD is paramount, as treating AD at these
stages would be the best approach to preventing severe progression [105]. We
established that at 11 months of age the Tg-AD rats exhibit impaired hippocampaldependent spatial learning and memory, as well as molecular markers of AD, such as
amyloid plaques, microglial activation, neuronal loss, and early signs of tau-PHF, the
latter reported by us [28].
Interestingly, we found that neuronal loss at 11 months of age was specific to the
DG and its subregions GCL and CA3c in the hippocampal tissue. The DG is known to be
vulnerable to aging and to be affected in the early stages of AD [106]. In fact it is reported
that in AD the GCL of the DG has impaired firing [107]. When the GCL is impaired, the
ability to identify/discriminate environmental cues during memory formation is greatly
diminished in spatial learning/memory [108]. These data support our findings that at 11
months of age, Tg-AD rats exhibit a significant impairment in two separate hippocampal-
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dependent behavioral tasks where the use of environmental cues is necessary to
evaluate learning/memory.
The relative abundance of the four prostanoids that we measured in hippocampal
tissue was, in descending order, PGD2, TxB2, PGE2, and PGJ2. PGD2 was by far the
most abundant at ~46.2pg/mg wet tissue. PGD2 was ~ 3-fold higher than TxB2, ~16-fold
higher than PGE2, and ~28-fold higher than PGJ2, all reported as an average between
WT and Tg-AD rats since there was no significant difference between the two genotypes.
Other studies confirm our finding that PGD2 is the most abundant PROSTAGLANDIN in
the brain, including in human brains [99, 109-111]. Alternatively, studies using
radioimmunoassays to measure PGD2 levels in brains of male Wistar rats killed by
microwave irradiation, reported significantly lower PGD2 levels, such as 2.3pg/mg wet
tissue, thus almost 20 fold less than what we found [112]. This discrepancy can be
attributed to the different methodology used, radioimmunoassays in the older studies
[112] versus quantitative LC-MS/MS in the most recent studies [99] and our studies. LC–
MS/MS exhibits superior sensitivity, accuracy, efficiency, and lack of cross-reactivity
compared to radioimmunoassays [113, 114].
PGD2 levels were equivalent in Tg-AD and WT rats. In contrast, one study
reported that PGD2 levels were significantly higher in post-mortem frontal cerebral cortex
tissue from AD patients compared to age matched controls [115]. Moreover, others
demonstrated that PGD2 levels increase significantly by as much as 6-fold in the
hippocampal and/or cerebral cortical tissue of male Sprague-Dawley rats following
traumatic brain injury [116] or brain ischemia [99, 117, 118]. Several factors could explain
why the levels of PGD2 were equivalent in the hippocampus of 11-month Tg-AD and WT
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rats. Firstly, the studies with the human AD cases measured PGD2 levels in a different
brain area, i.e. the cerebral cortex [115]. Secondly, prostaglandin levels were assessed
in the human cerebral cortices upon a 30-min incubation of the tissue at 37°C, thus
assessing PGD2 produced de novo during those 30-min. Under these conditions, PGD2
levels were significantly (~2-fold) higher in the AD cases than in controls. In contrast,
there were no marked differences for PGE2 between the AD cases and controls [115].
Thirdly, the short half-life of PGD2 could explain the discrepancy between our studies and
those involving different forms of rat brain injury. The half-life of PGD2 in mice was
estimated to be 1.6 min in the brain and 1.5 min in the blood [119]. Therefore, the increase
in the levels of PGD2 under a chronic condition, such as in AD and measured in our
studies, could be harder to detect than soon after brain injury such as that induced by
traumatic brain injury [116] or brain ischemia [99, 117, 118]. Although the exact cause of
the PGD2 increase is unclear, PGD2 production could be accelerated to compensate for
neuronal damage, and possibly enhance neuronal activity in the injured brain, as
suggested by [115]. Clearly, further investigation into this matter is needed.
The biologic actions of PGD2 are elicited through binding to its receptors DP1 and
DP2 on specific cell types. In the brain, DP1 was detected in microglia [120], astrocytes
[120], and neurons [83]. Moreover, DP1 was specifically localized in microglia and
reactive astrocytes associated with senile plaques in the cerebral cortex of AD patients
and of Tg2576 mice, a model of AD [35]. In our studies with 11-month Tg-AD and WT
rats, we detected changes in hippocampal microglial numbers but not in astrocytes, thus
we investigated DP1 distribution among the three microglia phenotypes, i.e. ramified,
reactive and amoeboid. Notably, in the hippocampal hilar subregion, Tg-AD rats had
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significantly fewer ramified, but more reactive and almost double amoeboid microglia than
controls. Thus, the Tg-AD rats at 11 months of age, exhibited a shift from a
neuroprotective state typical of ramified microglia, to more of a neurotoxic and overactive
state attributable to amoeboid microglia. This was expected as the latter state is
associated with neurodegeneration [121].
We established that DP1/microglia co-localization at the hippocampal hilar
subregion increased the most (3.2-fold) in amoeboid microglia of Tg-AD rats compared
to controls. We propose that enhanced DP1/amoeboid microglia co-localization is an
early marker of neurodegeneration. In fact, microglial overactivation and recruitment are
induced by Aβ, leading to microglia clustering around Aβ aggregates at an early stage
prior to neuropil damage in AD patients [121]. Furthermore, microglia-mediated
neurotoxicity manifested by the production of pro-inflammatory cytokines such as TNFα
and IL-1β, reactive oxygen/nitrogen species, and chemokines [87], tends to be
progressive potentially contributing to the progressive nature of AD [121].
Whether the increase in DP1/amoeboid microglia co-localization contributes to the
neurodegenerative process or is a compensatory mechanism, remains to be established.
Both DP1 agonists and antagonists can be protective in the brain and/or spinal cord,
depending on the type of injury . On the one hand, DP1 agonists such as BW245C protect
against glutamate toxicity and ischemic stroke induced in rodents [83, 122]. The benefits
of DP1 activation are mediated by increased cAMP synthesis that is instrumental in
converting pro-inflammatory neurotoxic microglia towards a tissue reparative antiinflammatory phenotype [123]. Among other effects, DP1 activation facilitates
vasodilation, thus protecting the brain from ischemic stroke caused by brain blood vessels
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becoming clogged [122]. DP1 activation also regulates sleep by stimulating adenosine
formation and subsequently activating the adenosine receptor A2A [62]. Studies with mice
showed that sleep drives Aβ clearance from the adult brain [124]. Both ischemic stroke
and sleep dysregulation facilitate the progression of AD pathology [125, 126]. On the
other hand, by limiting bleeding in mice, DP1 antagonists such as laropiprant (MK-0524)
protect against hemorrhagic stroke caused by brain bleeding that affects its function [87].
Moreover, DP1 genetic ablation mitigated disease symptoms developed by a mouse
model of amyotrophic lateral sclerosis (ALS) [127]. DP1 inhibition mitigates the increase
in activated/amoeboid microglia associated with both hemorrhagic stroke and ALS [87,
127]. In conclusion, modulating DP1 function is a promising therapeutic strategy
applicable to different types of brain conditions and injuries related to AD.
In our studies with 11-month Tg-AD and WT rats, we confirmed that the DP2
receptor is highly expressed in hippocampal neurons, as previously shown by others [83].
DP2 is also expressed in astrocytes [120], but was not detected in microglia [27]. Since
astrocyte levels were stable in the hippocampus of Tg-AD compared to WT rats, we
focused our studies on DP2 and neuronal levels. Both neuronal and DP2 levels
decreased significantly in a parallel manner in the GCL of the hippocampal DG region of
Tg-AD rats compared with controls. We propose that the decline in DP2/neuronal levels
is tied to the rise in activated/amoeboid microglia. Thus, chronic PGD2 release as a result
on enhanced neuroinflammation linked to AD, could on the one hand damage neurons
via its DP2 receptor, and on the other hand increase the levels of activated/amoeboid
microglia via its DP1 receptor. The changes in DP1 and DP2 levels that we report here
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are regional and specific, as they were only detected in the hilar subregion and GCL of
the hippocampal DG area (Fig. 2.5 and 2.6).
RNAseq analysis of 33 genes involved in the PGD2 and PGE2 pathways,
demonstrated that mRNA transcript levels in whole (ventral and dorsal combined)
hippocampal tissue were the highest for LPGDS. Expression of LPGDS is upregulated in
AD phenotypes, correlates with Aβ plaque burden, and is associated with pathological
traits of AD, but not with ALS or Parkinson’s disease [33] [34]. In our current studies,
LPGDS mRNA and protein levels were similar in WT and Tg-AD rats. However, whether
changes occur in individual cell types and/or in specific hippocampal regions, like for the
PGD2 receptors, remains to be determined.
LPGDS also known as β-trace, is the primary PGD2 synthase in the brain, and is
one of the most abundant (26 µg/ml, 3% of total) CSF proteins, second only to albumin
[34, 128]. LPGDS has a dual function, as it produces PGD2 and also acts as a lipophilic
ligand-binding protein [128]. LPGDS is a major endogenous Aβ chaperone that inhibits
Aβ40/42 aggregation in vitro and in vivo, the latter when administered to mice
intraventricularly infused with Aβ42 [33]. In vitro studies also demonstrated that LPGDS
acts as a disaggregase by disassembling Aβ fibrils [34]. In the PNS, LPGDS contributes
to myelination during development [129], and potentially acts as an anti-inflammatory
agent under conditions of peripheral nerve injury [23]. In the latter studies, LPGDS
modulated the expression of the transcription factor Sox-2, which in the CNS regulates
oligodendrocyte proliferation and differentiation [102], and in the PNS is a negative
regulator of myelination [23, 103]. Out of the 33 Prostaglandin-associated genes that we
focused on in our RNAseq analysis, Sox-2 expression was the third highest after LPGDS
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and prostaglandin E synthase 3. Sox-2 is proposed to act as a protective factor in AD, as
(1) it interacts with APP and mediates α-secretase activation in human cells, (2) its downregulation in adult mouse brains induces neurodegeneration, and (3) its expression is
downregulated in the brains of AD patients [130, 131]. Overall, more research is needed
to establish whether modulating L-PDGS and Sox-2 has potential for preventing or
treating AD.
Our results from treating Tg-AD rats with timapiprant reveal that manipulating
PGD2 signaling with DP2 antagonists could potentially mitigate plaque load, neuronal
loss and microgliosis, in addition to improving cognitive outcomes in AD patients (Fig. 9).
In the brain, DP2 activation accelerates damage, as corroborated by studies with rat
hippocampal neuronal and organotypic cultures in paradigms of glutamate toxicity [78,
83] or aluminum overload [132], and in a rat model of type 2 diabetes [133]. In the latter
study, DP2 signaling promoted brain damage and inhibited autophagy by activating the
PI3K/AKT/mTOR pathway [133]. Moreover, DP2 signaling mediates depression as well
as cognitive dysfunction, supported by DP2-deficient mice exhibiting anti-depressant-like
activity in a chronic corticosterone-induced model of depression [134], and improved
cognition in an NMDA receptor antagonist-induced model of cognitive dysfunction [135].
These findings support that DP2 signaling has a negative impact on emotion and
cognition. Thus, selective DP2 receptor antagonists may represent an encouraging option
for treating some types of brain disorders. However, further studies are necessary to
establish the long-term safety and benefits of these drugs that could be used as a
monotherapy or in combination with other therapies aimed, for example, at reducing
amyloid plaque burden in AD.
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In conclusion, at the periphery, PGD2 is an established inflammatory mediator
[136], and its effects include enhancing vascular permeability [137], modulating
chemotaxis [138], antigen presentation [139], vasodilatation, bronchoconstriction, platelet
aggregation, glycogenolysis, allergic reaction, and intraocular pressure [62], as well as
resolving peripheral nerve injury [23]. In the CNS, PGD2 regulates sleep induction, body
temperature, olfactory function, nociception, neuromodulation, and protects the brain
from ischemic stroke [62]. Our current data suggest that, as an alternative to NSAIDs and
as a novel approach for treating neuroinflammation, manipulating PGD2 signaling with
for example DP2 receptor antagonists, could have a significant translational and
multifactorial potential as a therapeutic for AD.
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Figure 2.11 Scheme depicting the relevance of the PGD2 pathway in AD and its

potential as an AD therapeutic target demonstrated by timapiprant (TIMA), a DP2
antagonist.

Fig. 2.11. Tg-AD rats at 11 months of age exhibit AD pathology. We propose that manipulating PGD2
signaling through, for example DP2 receptor antagonists such as TIMA, could prevent/mitigate AD
pathology by several mechanisms. Further details are presented in the discussion, based on our
current results with the Tg-AD rat model treated with TIMA, and studies published by others. Figure
partially created with BioRender.com.
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Supplemental Fig. 2.1.
Subregions within the dentate gyrus (NeuN IHC for a WT female rat)

HL, hilar; GCL, granular cell layer, CA, cornu ammonis
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Supplemental Fig. 2.2
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Supplemental Fig. 2.3
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Supplemental Fig. 2.4
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Supplemental Fig. 2.5
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Supplemental Fig. 2.6
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Supplemental Fig. 2.7
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Supplemental Fig. 2.8
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Supplemental Fig. 2.9
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Supplemental Fig. 2.10A
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Supplemental Fig. 2.10B
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Supplemental Fig. 2.10C
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Supplemental Fig. 2.10D

D.
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Supplemental Fig. 2.11
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Supplemental Fig. 2.12
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Supplemental Table 2.1: DP1 levels (% signal) across hippocampal regions

SB
CA1
CA3
DG
HL

WT mean ± SEM
n = 12
3.88 ± 0.16
3.50 ± 0.20
3.91 ± 0.16
4.33 ± 0.23
5.22 ± 0.22

Tg-AD mean ± SEM
n = 11
4.05 ± 0.23
3.97 ± 0.22
4.24 ± 0.25
4.63 ± 0.16
5.34 ± 0.22

p-value

t-statistics

0.27
0.06
0.13
0.15
0.36

t=0.15, df=17.08
t=1.58, df=20.76
t=1.14, df=17.23
t=1.06, df=19.31
t=0.36, df=20.99

Values represent the percent of the signal (DP1+) detected within a specific area (= 100%, µm2)
as explained under materials and methods. Abbreviations: DP1, prostaglandin D2 receptor 1;
WT, wild type; Tg-AD, transgenic rat model of Alzheimer’s disease; SEM, standard error of the
mean; SB, subiculum; CA, cornu ammonis; DG, dentate gyrus; HL, hilar.

Supplemental Table 2.2: Microglia levels (Iba1+, counts/nm2) across hippocampal regions

SB
CA1
CA3
DG
HL

WT mean ± SEM
n = 12
214.90 ± 7.75
231.10 ± 8.65
246.10 ± 7.60
226.10 ± 6.86
40.70 ± 2.47

Tg-AD mean ± SEM
n = 11
235.80 ± 9.08
263.00 ± 11.37
269.20 ± 12.27
268.20 ± 11.20
58.95 ± 5.24

p-value

t-statistics

0.05
0.02
0.06
0.003
0.003

t=1.75, df=20.16
t=2.23, df=19.10
t=1.60, df=16.89
t=3.20, df=16.76
t=3.15, df=14.28

Values represent the microglia counts (Iba1+) detected within a specific area (nm2) as explained
under materials and methods. Abbreviations: Iba1, ionized calcium binding adaptor molecule 1;
WT, wild type; Tg-AD, transgenic rat model of Alzheimer’s disease; SEM, standard error of the
mean; SB, subiculum; CA, cornu ammonis; DG, dentate gyrus; HL, hilar.
Supplemental Table 2.3: DP1 and microglia (Iba1+) co-localization across hippocampal
regions

SB
CA1
CA3
DG
HL

WT mean ± SEM
n = 12
171.70 ± 11.07
178.60 ± 11.93
206.50 ± 9.71
190.50 ± 8.70
35.34 ± 2.26

Tg-AD mean ± SEM
n = 11
178.30 ± 7.08
189.30 ± 9.21
218.50 ± 10.00
226.40 ± 12.61
52.54 ± 5.27

p-value

t-statistics

0.31
0.24
0.20
0.02
0.005

t=0.50, df=18.44
t=0.71, df=20.15
t=0.86, df=20.87
t=2.35, df=18.07
t=2.00, df=13.60

Values represent microglia counts (Iba1+) co-localized with DP1 signal within a specific area
(nm2) as explained under materials and methods. Abbreviations: DP1, prostaglandin D2
receptor 1; Iba1, ionized calcium binding adaptor molecule 1; WT, wild type; Tg-AD, transgenic
rat model of Alzheimer’s disease; SEM, standard error of the mean; SB, subiculum; CA, cornu
ammonis; DG, dentate gyrus; HL, hilar.
80

Supplemental Table 2.4: Astrocyte levels (GFAP, % signal) across hippocampal regions

SB
CA1
CA3
DG
HL

WT mean ± SEM
n = 12
4.42 ± 0.13
4.36 ± 0.11
4.45 ± 0.15
4.47 ± 0.12
4.65 ± 0.21

Tg-AD mean ± SEM
n = 11
4.56 ± 0.20
4.61 ± 0.17
4.65 ± 0.16
4.71 ± 0.12
4.99 ± 0.20

p-value

t-statistics

0.28
0.11
0.23
0.08
0.13

t=0.58, df=17.13
t=1.26, df=17.37
t=0.75, df=20.47
t=1.44, df=20.81
t=1.15, df=21.00

Values represent the percent of the signal (GFAP+) detected within a specific area (= 100%,
µm2) as explained under materials and methods. Abbreviations: GFAP, Glial fibrillary acidic
protein; WT, wild type; Tg-AD, transgenic rat model of Alzheimer’s disease; SEM, standard error
of the mean; SB, subiculum; CA, cornu ammonis; DG, dentate gyrus; HL, hilar.
Supplemental Table 2.5: Neuronal levels (NeuN, % signal) across hippocampal regions

SB
CA1
CA3
DG
HL

WT mean ± SEM
n = 12
5.55 ± 0.30
4.13 ± 0.13
6.38 ± 0.19
6.29 ± 0.37
6.70 ± 0.25

Tg-AD mean ± SEM
n = 11
5.55 ± 0.41
4.09 ± 0.21
6.11± 0.22
5.32 ± 0.38
5.76 ± 0.49

p-value

t-statistics

0.50
0.44
0.18
0.04
0.05

t=0.004, df=18.67
t=0.16, df=17.21
t=0.95, df=20.10
t=1.83, df=20.82
t=1.71, df=14.96

Values represent the percent of the signal (NeuN+) detected within a specific area (= 100%,
µm2) as explained under materials and methods. Abbreviations: NeuN, neuronal nuclei,
neuronal marker; WT, wild type; Tg-AD, transgenic rat model of Alzheimer’s disease; SEM,
standard error of the mean; SB, subiculum; CA, cornu ammonis; DG, dentate gyrus; HL, hilar.
Supplemental Table 2.6: DP2 levels (% signal) across hippocampal regions

SB
CA1
CA3
DG
HL

WT mean ± SEM
n = 12
4.35 ± 0.20
3.48 ± 0.16
3.85 ± 0.18
4.62 ± 0.17
5.29 ± 0.14

Tg-AD mean ± SEM
n = 11
4.36 ± 0.21
4.47 ± 0.25
4.21 ± 0.14
4.87 ± 0.13
5.44 ± 0.13

p-value

t-statistics

0.29
0.002
0.07
0.13
0.21

t=0.05, df=20.75
t=3.36, df=17.62
t=1.56, df=20.30
t=1.14, df=20.30
t=0.83, df=20.97

Values represent the percent of the signal (DP2+) detected within a specific area (= 100%, µm2)
as explained under materials and methods. Abbreviations: DP2, prostaglandin D2 receptor 2;
WT, wild type; Tg-AD, transgenic rat model of Alzheimer’s disease; SEM, standard error of the
mean; SB, subiculum; CA, cornu ammonis; DG, dentate gyrus; HL, hilar.
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Supplemental Table 2.7: DP2 and neuronal (NeuN+) co-localization across hippocampal
regions

SB
CA1
CA3
DG
HL

WT mean ± SEM
n = 12
51.69± 5.17
50.26 ± 4.11
47.33± 3.29
46.75± 3.13
67.27 ± 2.85

Tg-AD mean ± SEM
n = 11
47.96± 4.29
48.21 ± 3.71
44.44± 3.85
47.14± 3.89
67.48 ± 4.29

p-value

t-statistics

0.29
0.36
0.29
0.47
0.48

t=0.56, df=20.61
t=0.37, df=20.94
t=0.57, df=20.17
t=0.08, df=19.65
t=0.04, df=17.66

Values represent % co-localized NeuN and DP2 signals within a specific area (nm2) as
explained under materials and methods. Abbreviations: DP2, prostaglandin D2 receptor 2;
NeuN, neuronal nuclei, neuronal marker; WT, wild type; Tg-AD, transgenic rat model of
Alzheimer’s disease; SEM, standard error of the mean; SB, subiculum; CA, cornu ammonis;
DG, dentate gyrus; HL, hilar.
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Supplemental Table 2.8: RNA sequence analysis for selected prostaglandin pathway
genes

Gene
symbol

A. MALES (n = 5)
Fold
Function/Name
chan
ge

p
Valu
e

FD
R

Tg-AD
mean 
SEM

WT
mean 
SEM

358.94 
53.18

258.16 
23.38
113.72 
5.36

PROSTAGLANDIN D2 and J2
Ptgds

prostaglandin D2 synthase (brain)

1.83

0.212

Sox2

SRY (sex determining region Y)-box 2

-1.29

0.011

0.5
50

88.47  8.08

Ppard

peroxisome proliferator-activated receptor delta

-1.18

0.110

1

42.23  3.74

49.71  3.26

1.06

0.474

1

28.32  0.65

26.71  0.77

-1.08

0.507

1

15.53  0.55

16.76  0.81

1.00

1.000

1

4.93  0.26

4.93  0.26

-1.09

0.600

1
1

3.7  0.37

4.04  0.25

1.19  0.32

1.24  0.15

1
1

0.34  0.10

0.64  0.13

0.51  0.18

0.59  0.06

Pprc1
Ppargc1a
Ppargc1b
Ppara

peroxisome proliferator-activated receptor
gamma, coactivator-related 1
peroxisome proliferator-activated receptor
gamma, coactivator 1 alpha
peroxisome proliferator-activated receptor
gamma, coactivator 1 beta
peroxisome proliferator activated receptor
alpha

1

Hpgds

hematopoietic prostaglandin D synthase

-1.04

0.890

Ptgdrl

prostaglandin D2 receptor-like (in rat,
orthologous to human DP1)

-1.87

0.296

Ptgdr2

prostaglandin D2 receptor 2 (DP2)

-1.16

0.667

Pparg

peroxisome proliferator-activated receptor
gamma

1.07

0.872

1

0.26  0.03

0.24  0.02

Ptgdr

prostaglandin D2 receptor (DP1)

3.30

0.164

1

0.11  0.05

0.03  0.03

PROSTAGLANDIN E2
Ptges3

prostaglandin E synthase 3 (cytosolic)

-1.03

0.748

Ptges2

prostaglandin E synthase 2

-1.00

0.975

prostaglandin E synthase 3-like 1

-1.06

0.582

Ptges3l1
Ptger1

prostaglandin E receptor 1 (subtype EP1)

-1.31

0.027

Ptger3

prostaglandin E receptor 3 (subtype EP3)

1.56

0.095

Ptger2

prostaglandin E receptor 2 (subtype EP2)

-1.02

0.946

Ptges

prostaglandin E synthase

1.15

0.712

Ptger4

prostaglandin E receptor 4 (subtype EP4)

1.94

0.082

1
1
1

156.20 
8.97

160.45 
5.78

46.14  0.98

46.22  0.93

16.29  0.87

17.32  1.22

0.8
25

6.59  0.17

8.65  0.54

1
1

1.58  0.20

1.01  0.18

0.97  0.05

0.99  0.21

1
1

1.06  0.29

0.93  0.26

0.44  0.12

0.23  0.06

1
1

4.51  0.81

4.60  0.36

1.01  0.14

1.52  0.16

88.12  5.78

102.54 
6.78

THROMBOXANE
Tbxas1

thromboxane A synthase 1, platelet

-1.02

0.906

Tbxa2r

thromboxane A2 receptor

-1.51

0.076

PHOSPHOLIPASES, CYCLOOXYGENASES & RELATED
Ptgr2

prostaglandin reductase 2

-1.16
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0.091

1

Ptgs2
Ptgs1
Pla2g4a
Hpgd
Ptgr1

prostaglandin-endoperoxide synthase 2 (COX2)
prostaglandin-endoperoxide synthase 1 (COX1)
phospholipase A2, group IVA (cytosolic,
calcium-dependent)
hydroxyprostaglandin dehydrogenase 15
(NAD)
prostaglandin reductase 1

-1.20

0.473

1

18.51  2.86

22.28  5.27

-1.13

0.328

1

17.52  2.15

19.86  2.13

-1.02

0.877

1

7.70  0.43

7.87  0.65

1.17

0.562

2.97  0.57

2.53  0.45

1.03

0.939

1
1

1.07  0.14

1.05  0.23

1
1
1
1
1

40.05  5.40

42.33  5.36

1.76  0.29

1.40  0.21

1.22  0.67

0.65  0.21

0.11  0.05

0.19  0.04

38.78  1.20

35.15  2.47

Tg-AD
mean 
SEM

WT
mean 
SEM

1

189.32 
8.05

282.71 
94.63

1

75.22  5.32

79.43  8.82

37.98  0.93

38.41  0.50

OTHERS
Ptgfrn

prostaglandin F2 receptor inhibitor

-1.06

0.702

Ptgis

prostaglandin I2 (prostacyclin) synthase

1.26

0.508

Ptgfr

prostaglandin F receptor

1.90

0.246

Ptgir

prostaglandin I2 (prostacyclin) receptor (IP)

-1.65

0.313

Cbr1

carbonyl reductase 1

1.10

0.250

Gene
symbol

B. FEMALES (n = 5)
Fold
Function/Name
chan
ge

P
Valu
e

FD
R

PROSTAGLANDIN D2 and J2
Ptgds

prostaglandin D2 synthase (brain)

-1.49

0.070

Sox2

SRY (sex determining region Y)-box 2

-1.06

0.636

-1.01

0.904

1.07

0.471

1

32.48  1.26

30.34  0.93

-1.06

0.615

1

19.07  1.01

20.22  1.51

1.01

0.950

1

6.67  0.89

6.58  0.51

-1.01

0.956

3.63  0.16

3.66  0.39

Ppard
Pprc1
Ppargc1a
Ppargc1b
Ppara

peroxisome proliferator-activated receptor
delta
peroxisome proliferator-activated receptor
gamma, coactivator-related 1
peroxisome proliferator-activated receptor
gamma, coactivator 1 alpha
peroxisome proliferator-activated receptor
gamma, coactivator 1 beta
peroxisome proliferator activated receptor
alpha

1

1

Hpgds

hematopoietic prostaglandin D synthase

1.31

0.408

1

1.48  0.30

1.13  0.19

Ptgdrl

prostaglandin D2 receptor-like (in rat,
orthologous to human DP1)

1.65

0.304

1

0.71  0.11

0.43  0.18

Ptgdr2

prostaglandin D2 receptor 2 (DP2)

-1.17

0.676

1

0.35  0.08

0.41  0.03

Pparg

peroxisome proliferator-activated receptor
gamma

1.13

0.769

0.28  0.03

0.24  0.06

Ptgdr

prostaglandin D2 receptor (DP1)

-3.01

0.187

0.03  0.03

0.09  0.06

PROSTAGLANDIN E2
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1
1

1

169.56 
3.85

165.83 
3.29

0.760

1

47.98  2.39

46.52  2.50

-1.01

0.926

1

16.27  0.70

16.46  0.52

prostaglandin E receptor 1 (subtype EP1)

-1.02

0.902

1

5.38  0.36

5.51  0.31

Ptger3

prostaglandin E receptor 3 (subtype EP3)

-1.09

0.739

1

1.41  0.09

1.54  0.15

Ptger2

prostaglandin E receptor 2 (subtype EP2)

1.00

0.994

1

1.14  0.29

1.14  0.04

Ptges

prostaglandin E synthase

-1.86

0.089

1

0.62  0.16

1.18  0.21

Ptger4

prostaglandin E receptor 4 (subtype EP4)

-1.11

0.780

1

0.35  0.07

0.39  0.04

Ptges3

prostaglandin E synthase 3 (cytosolic)

1.02

0.779

Ptges2

prostaglandin E synthase 2

1.03

prostaglandin E synthase 3-like 1

Ptger1

Ptges3l1

THROMBOXANE
Tbxas1

thromboxane A synthase 1, platelet

1.19

0.382

1

3.83  0.14

3.21  0.21

Tbxa2r

thromboxane A2 receptor

-1.23

0.549

1

1.00  0.22

1.24  0.34

1.03

0.757

1

72.66  3.39

70.62  3.63

-1.09

0.604

21.64  2.25

23.62  3.51

1.07

0.612

17.71  0.71

16.61  1.75

-1.09

0.599

6.73  0.43

7.36  0.62

1.26

0.358

3.64  0.13

2.87  0.57

1.35

0.361

1

0.91  0.12

0.68  0.12

PHOSPHOLIPASES, CYCLOOXYGENASES & RELATED
Ptgr2
Ptgs2
Ptgs1
Pla2g4a
Hpgd
Ptgr1

prostaglandin reductase 2
prostaglandin-endoperoxide synthase 2 (COX2)
prostaglandin-endoperoxide synthase 1 (COX1)
phospholipase A2, group IVA (cytosolic,
calcium-dependent)
hydroxyprostaglandin dehydrogenase 15
(NAD)
prostaglandin reductase 1

1
1
1
1

OTHERS
Ptgfrn

prostaglandin F2 receptor inhibitor

-1.42

0.027

1

32.58  0.97

46.23  9.27

Ptgis

prostaglandin I2 (prostacyclin) synthase

-1.13

0.700

1

1.12  0.24

1.27  0.17

Ptgfr

prostaglandin F receptor

-1.08

0.832

1

0.51  0.09

0.55  0.11

Ptgir

prostaglandin I2 (prostacyclin) receptor (IP)

-1.19

0.734

1

0.18  0.03

0.21  0.09

Cbr1

carbonyl reductase 1

-1.11

0.377

38.02  0.70

42.14 
4.51

1

Within each functional group, genes are listed in decreasing order of expression levels
(RPM mean  SEM) for Tg-AD (n = 5) and WT (n = 5) male (A) and female (B) rats.
Gene functions/names, fold change, P values, and FDR are also included.
Abbreviations: WT, wild type; Tg-AD, transgenic rat model of Alzheimer’s disease; SEM,
standard error of the mean; RPM, reads per million; FDR, false discovery rates.
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Supplemental Table 2.9: Semi-quantification of protein expression in hippocampal tissue.
WT mean ± SEM Tg-AD mean ± SEM
p-value
t-statistics
n=6
n=6
FL-APP/actin
1.00 ± 0.22
5.62 ± 0.60
<0.001 t=7.23, df=6.30
Aβ/GAPDH
1.00 ± 0.20
32.60 ± 8.73
0.008 t=3.62, df=5.01
COX-2/tubulin
1.00 ± 0.18
1.68 ± 0.38
0.07
t=1.63, df=7.15
DP1/GAPDH
1.00 ± 0.08
1.36 ± 0.08
0.16
t=1.04, df=8.96
DP2/GAPDH
1.00 ± 0.16
0.79 ± 0.09
0.15
t=1.13, df=7.95
L-PGDS/GAPDH
1.00 ± 0.08
1.09 ± 0.14
0.30
t=0.55, df=8.05
PPARγ/actin
1.00 ± 0.18
0.68 ± 0.14
0.10
t=1.40, df=9.53
Sox-2/actin
1.00 ± 0.32
0.72 ± 0.27
0.24
t=0.73, df=9.19
Values represent the respective protein amounts detected in hippocampal homogenates.
Abbreviations: WT, wild type; Tg-AD, transgenic rat model of Alzheimer’s disease; SEM,
standard error of the mean; FL-APP, full length amyloid precursor protein; Aβ, amyloid β;
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; COX-2, cyclooxygenase-2; DP1,
prostaglandin D2 receptor 1; DP2, prostaglandin D2 receptor 2; L-PGDS, lipocalin-type
prostaglandin D synthase; PPARγ, peroxisome proliferator activated receptor gamma; Sox-2,
SRY-box transcription factor 2.
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Supplemental Table 2.10 A-D: aPAT out measures Latency to 1st Entrance

Trial

TGNT
mean
n=9

TGTR
mean
n=9

WTNT
mean
n=9

WTTR
mean
n=9

post hoc
(TGNT vs
TGTR)

post hoc
(TGNT vs
WTNT)

post hoc
(WTNT vs
WTTR)

1

24.58

61.70

36.41

28.82

>0.99

>0.99

>0.99

2

22.93

174.7

191.1

57.93

0.30

0.12

0.61

3

38.32

222.5

253.8

276.9

0.12

0.02

>0.99

4

39.34

196.3

239.7

104.2

0.27

0.04

0.59

5

95.59

344.9

138.6

377.3

0.01

>0.99

0.06

6

96.91

268.3

89.88

387.8

0.18

>0.99

0.009

Fixed Effects
(TGNT vs TGTR)

Overall p value

F-statistic (DFn, DFd)

Trial (Trials 1-6)

0.02

F (5, 80) = 2.932

Treatment (Trials 1-6)

0.002

F (1, 16) = 13.87

Fixed Effects
(TGNT vs WTNT)

Overall p value

F-statistic (DFn, DFd)

Trial (Trials 1-6)

0.14

F (5, 80) = 1.710

Genotype (Trials 1-6)

0.02

F (1, 16) = 6.122

Fixed Effects
(WTNT vs WTTR)

Overall p value

F-statistic (DFn, DFd)

Trial (Trials 1-6)

0.001

F (5, 85) = 4.506

Treatment (Trials 1-6)

0.32

F (1, 17) = 1.050
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Supplemental Table 2.11 A-D: aPAT out measures Latency to 2nd Entrance

Trial

TGNT
mean
n=9

TGTR
mean
n=9

WTNT
mean
n=9

WTTR
mean
n=9

post hoc
(TGNT vs
TGTR)

post hoc
(TGNT vs
WTNT)

post hoc
(WTNT vs
WTTR)

1

88.12

218.6

136.3

116.1

0.71

>0.99

>0.99

2

205.2

413.9

379.8

278.9

0.20

0.40

0.86

3

257.6

417.9

445.0

505.7

0.49

0.32

0.99

4

276.9

501.0

481.2

320.5

0.14

0.23

0.41

5

415.0

492.9

356.3

485.4

0.97

>0.99

0.66

6

400.6

436.0

382.0

581.2

>0.99

>0.99

0.18

Fixed Effects
(TGNT vs TGTR)

Overall p value

F-statistic (DFn, DFd)

Trial (Trials 1-6)

<0.001

F (5, 80) = 6.307

Treatment (Trials 1-6)
Trial x Treatment (Trials 16)

0.03

F (1, 16) = 5.373

0.59

F (5, 80) = 0.7470

Fixed Effects
(TGNT vs WTNT)

Overall p value

F-statistic (DFn, DFd)

Trial (Trials 1-6)

<0.001

F (5, 80) = 6.475

Genotype (Trials 1-6)
Trial x Treatment (Trials 16)

0.17

F (1, 16) = 2.051

0.12

F (5, 80) = 1.832

Fixed Effects
(WTNT vs WTTR)

Overall p value

F-statistic (DFn, DFd)

Trial (Trials 1-6)

<0.001

F (5, 85) = 10.77

Treatment (Trials 1-6)
Trial x Treatment (Trials 16)

0.75

F (1, 17) = 0.1046

0.02

F (5, 85) = 2.888
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Supplemental Table 2.12: Antibodies used for IHC and WB analyses of hippocampal tissue
Company

Catalog
Number

Aβ (4G8)

Biolegend

#800708

Aβ (6E10)

Biolegend

#SIG-39320

Cell Signaling

#12282

DP1

Cayman
Chemical

#101640

Rabbit Polyclonal

DP2

Invitrogen

#PA5-20332

Rabbit Polyclonal

Antibody

Species/Type

Dilution

Assay

1:1000

IHC

1:2000

WB

1:1000

WB

PRIMARIES

COX-2 (D5H5)

FL-APP (22C11)
GAPDH (6C5)
GFAP (GA5)
Iba1
L-PGDS
NeuN
PPARγ
Sox-2
β-Actin (AC-74)
β-Tubulin (TUBB3)
SECONDARIES
Alexa Fluor 488,
Donkey anti-Mouse IgG
(H+L)
Alexa Fluor 488, Goat
anti-Chicken IgY (H+L)
Alexa Fluor 568, Goat
anti-Rabbit IgG (H+L)
Goat Anti-Rabbit IgG (H
+ L)-HRP
Hoarse Anti-Mouse IgG
(H + L)-HRP

Millipore
Sigma
Millipore
Sigma
Millipore
Sigma
Synaptic
Systems
Abcam
Millipore
Sigma
Abcam
Abcam

#MAB348
#MAB374
#MAB360
#234006
#ab182141
#ABN91
#ab209350
#ab97959

Sigma-Aldrich

#A2228

Covance

#MMS-435P

ThermoFisher

#A-21202

ThermoFisher

#A-11039

ThermoFisher

#A-11011

Cell Signaling

#7074

Cell Signaling

#7076

Mouse
Monoclonal
Mouse
Monoclonal
Rabbit
Monoclonal

Mouse
Monoclonal
Mouse
Monoclonal
Mouse
Monoclonal
Chicken
Polyclonal
Rabbit Polyclonal
Chicken
Polyclonal
Rabbit Polyclonal
Rabbit Polyclonal
Mouse
Monoclonal
Mouse
Monoclonal
Mouse
Secondary
Chicken
Secondary
Rabbit
Secondary
Rabbit
Secondary
Mouse
Secondary

1:200 for
both
1:1000 for
both

IHC, WB
IHC, WB

1:2000

WB

1:2000

WB

1:1000

IHC

1:500

IHC

1:1000

WB

1:500

IHC

1:1000
1:2000

WB
WB

1:10000

WB

1:10000

WB

1:250

IHC

1:500

IHC

1:250

IHC

1:300010000
1:300010000

WB
WB

Abbreviations: IHC, immunohistochemistry; WB, western blot; Aβ, amyloid β; COX-2,
cyclooxygenase-2; DP1, prostaglandin D2 receptor 1; DP2, prostaglandin D2 receptor 2; FL-APP,
full length amyloid precursor protein; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GFAP,
glial fibrillary acidic protein; Iba1, ionized calcium binding adaptor molecule 1; NeuN, neuronal
nuclei; neuronal marker; PPARγ, peroxisome proliferator activated receptor gamma; Sox-2, SRYbox transcription factor 2.

89

CHAPTER III

Human polymorphisms in the PGD2 pathway

3.1. Human polymorphisms in the PGD2 pathway
3.2. Human polymorphisms linked to NSAID treatment efficacy
3.3. Genomic screening: patient selection for AD clinical trials

Charles Henry Wallace
Department of Biological Sciences
Hunter College of the City University of New York,
New York, New York 10065
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3.1. Human polymorphisms in the PGD2 pathway
It is well established that certain genetic polymorphisms affect the response to
target-specific treatments. Thus, I investigated published literature reporting possible
polymorphisms in the PGD2 pathway that may affect disease state and/or treatment
efficacy.
For the DP1 gene (PTGDR), DP1 expression is highest in individuals with the
promoter haplotypes CCC and CCT compared to those who carry the TCT (at positions
–549, –441, and –197) (rs# unavailable) [140]. Polymorphisms in humans for PTGDR
have been explored for asthma, and a meta-analysis revealed that the single -549 C/T
polymorphism increased asthma susceptibility for adults.
For the DP2 gene (PTGDR2 or CRTH2), the -466T>C polymorphism (rs#
unavailable) was identified, and it showed increased adverse events and had higher DP2
expression [141]. To my knowledge, these DP1 and DP2 polymorphisms have not been
investigated in patients for AD or any neuroinflammatory diseases.
For the LPGDS gene (PTGDS) LPGD has been investigated in the CSF for
neurodegenerative diseases and sleep, and in the serum for coronary artery disease and
atherosclerosis [142, 143]. Only one polymorphism for LPGDS: 4111A>C was found to
be associated with severity of carotid atherosclerosis [144]. However, no LPGDS
polymorphisms have been identified in the CSF of related neurodegenerative diseases
so this should be investigated.
For the HPGDS gene, polymorphisms have been identified but there seems to be
no link to HPGDS expression or function [145, 146]. For HPGDS, polymorphisms in
microglia merit investigation since there is no literature on this issue [36].
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3.2. Human polymorphisms linked to NSAID treatment efficacy
I also investigated published literature reporting links between allele expression or
polymorphisms and NSAID treatment efficacy. NSAIDs have been considered a possible
therapeutic for AD, but results are often complex to interpret and sometimes subset
analysis help us understand more about treatment strategies. For example, in the
Cardiovascular Health Cognition Study those individuals with an APOE ε4 allele had a
reduced risk for AD after NSAID use, compared to those with the APOE ε4 allele [147].
Transgenic mice that express the human APOE ε4 allele exhibit a greater brain
inflammatory response than those that do not express human APOE ε4 [148]. It is
proposed that APOE ε4 modulates the NFκB signaling [148].
NSAIDs are known to have adverse effects such as gastrointestinal, renal, and
cardiovascular (CVD) complications [50-52]. This adverse reaction to NSAIDS from many
patients is known as NSAID-exacerbated respiratory disease (NERD), and it has genetic
risks from polymorphisms on the COX-1 gene (PTGS1), making patients hypersensitive
to NSAIDs, and causing inflammation and asthma like symptoms [149]. COX-1 gene
polymorphisms have been rigorously investigated for the risk of adverse side effects to
NSAIDs [150-152]. Patients with the polymorphisms for rs10306187A>C,G and
rs10306188A>G had increased hypersensitivity to NSAIDs, and those with the haplotype
rs10306187A>C,G + rs10306188A>G had an even greater sensitivity [150]. Patients that
were homozygous for the rs10306135A>T alleles had less CVD, likely due to lower COX1 expression [151, 153]. The haplotype polymorphism rs10306114A>G + rs3842787C>T
had an increased risk of bleeding; notably this haplotype had “linkage disequilibrium”
meaning that the polymorphisms always co-occurred [154]. Only the polymorphism in
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the exon rs5789C>A due to a missense mutation, had a reduced COX-1 efficiency [155].
The COX-2 gene (PTGS2) is often thought as synonymous to inflammation,
because it is inducible after an insult [31]. The COX-2 gene polymorphism rs20417C>G,T
gives rise to COX-2 that is less active and has a lower inflammatory response after insult
[156]. This COX-2 polymorphism was found to be protective in CVD and AD [157, 158].
One meta-analysis of 7 studies looked at the lower risk of this COX-2 polymorphism
specifically in AD [159]. The resulting analysis supported this hypothesis, as across
cohorts the AD risk was lower [159].

3.3. Genomic screening: patient selection for AD clinical trials
Based on the studies discussed above, genomic polymorphisms should be
considered in clinical trials. I suggest an exclusion criterion in future clinical trials (1) for
those with COX-1 polymorphisms that are associated with adverse side effects from
NSAIDs, (2) for those with a less active COX-2 promoter region that would likely not
experience substantial benefits, (3) for those without an APOE ε4 allele. I think this
exclusion criterion should also be applied when testing NSAIDs or drugs in prostaglandin
metabolism. I hypothesize that those individuals who meet this criterion (1) would be less
likely to have adverse side effects from NSAIDs, and (2) are likely to experience an
elevated inflammatory response, which may be leading to AD acceleration.
For DP1, DP2, LPGDS and HPGDS I propose that more studies are needed to
address how these polymorphisms may be altering their expression or function in AD.

93

CHAPTER IV

DIAZOXIDE/DIBENZOYLMETHANE CO-TREATMENT ATTENUATES
COGNITIVE IMPAIRMENT AND ALTERS THE TRANSCRIPTOME
IN A TRANSGENIC RAT ALZHEIMER’S MODEL

Charles Henry Wallace
Department of Biological Sciences,
Hunter College of the City University of New York,
New York, New York 10065

NOTE: The effects of the DZ/DIB co-treatment on Tg-AD rats was complemented by studies
carried-out by another graduate student in our laboratory, Giovanni Oliveros. Giovanni
investigated by immunohistochemistry, the effect of the double drug treatment on AD pathology.
His data are not discussed here.
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4.1. ABSTRACT
Alzheimer’s disease (AD) is a multifactorial disease for which therapeutic efficacy should
benefit from a multi-target approach. Thus, we utilized a combination drug treatment of
diazoxide (DZ) and dibenzoylmethane (DIB). DZ is a potassium channel activator. DIB
restores eIF2B activity, thus reversing stress-induced translational depression. Previous
studies examined each drug’s individual therapeutic benefits on attenuating
neurodegeneration and apoptosis in other animal model systems. However, their
combined treatment potential was not addressed. To test the efficacy of this combined
treatment we used the Fisher transgenic 344-AD rat model of AD (Tg-AD). We assessed
cognitive performance in 4-month (pre-pathology) and 11-month old (moderate
pathology) DZ/DIB treated Tg-AD and WT rats, and compared to untreated age-matched
littermates. We tested spatial-working memory performance using RAM. As expected, at
4 months of age the Tg-AD rats did not exhibit cognitive impairment assessed with RAM,
and DZ/DIB treatment had no effect on these rats. At 11 months of age untreated Tg-AD
rats exhibited significant working memory deficits compared to untreated WT rats.
Notably, the DZ/DIB treatment mitigated the working memory deficits in Tg-AD treated
compared to untreated Tg-AD rats. WT rats were not affected by the combined treatment.
Our transcriptome analysis revealed two potential early biomarkers for AD, i.e. EGR2
(early growth response 2) and HISIT1H2AA (histone H2AA) genes. This is based on the
finding that at 4 months of age, out of 17,168 rat genes analyzed by RNAseq, only the
expression levels of these two genes significantly changed. Additionally, at 4 months of
age, DZ/DIB co-treatment upregulated many genes discussed below that are normally
downregulated by AD pathology and/or ageing. Our results strongly support that DZ/DIB
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co-treatment is an effective strategy to mitigate AD cognitive deficits due to its multi-target
approach that affects multiple signaling pathways.

4.2. INTRODUCTION
AD is the most common form of dementia with a growing prevalence every year
[160]. AD is a multifaceted neurodegenerative disease that involves neuronal death,
chronic neuroinflammation, ER stress, oxidative stress among other signs of brain
damage with an increasing disease state over time [161, 162]. Common therapeutics in
the AD drug development pipeline are mono-target therapeutics, for example either A
amyloid- or tau-related [163]. It is time consuming and expensive to develop new drugs
that cross the BBB and have success in preclinical models, and most of the drugs that
progress to the clinical trial stage fail. Unfortunately, between 2002 and 2012 AD
therapeutics in the drug pipeline had a disappointing failure rate of 99.6% with many of
these being A amyloid- or tau-related [68]. Recently, a controversial FDA approval
followed by backlash was made on a single target amyloid-related drug, Aduhelm [164].
Alternatively, investigators have begun testing the use of multi-target drugs that
work on multiple biological pathways, often referred to as polypharmacology [70, 165].
Perhaps the strongest testimony for polypharmacology is the current effective treatment
of the AIDS virus [166]. Additionally, drug repurposing has many benefits and many
studies use repurposing for the COVID-19 pandemic as outlined in the following review
[167]. Some benefits of drug repurposing include low development costs, known safety
profiles, and bringing existing therapeutics to new patient populations [69]. Through
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computational studies, drugs intended for other purposes that work on biological networks
can be repurposed for AD.
In our current study, we utilized drug repurposing, polypharmacology, and
combination therapy, with the tandem treatment of DZ and DIB. DZ has been used for
decades for its cardioprotective effects [168]. DZ is a benzothiadiazine derivative that is
an agonist to mitochondrial ATP sensitive potassium channels, which increases
intracellular K+ levels. An increase in intracellular K+ would reduce abnormally elevated
intracellular Ca2+ concentrations commonly found in AD, and were shown to cause
oxidative stress and lead to neurodegeneration [169]. DZ administered intraperitoneally
prevented caspase-dependent apoptosis via BCL-2 activation and BAX inhibition in rat
hippocampus [170]. Moreover, treatment of PC12 cells with DZ prevented apoptosis
through caspase-dependent and independent means [171]. DZ also mitigated cognitive
deficits and histopathology in the 3xTgAD mouse model of AD, although neuronal loss
was not addressed [172].
DIB is a β-diketone minor constituent and a β-ketone analog to curcumin found in
licorice among other plants [173]. DIB and/or DIB derivatives were used in preclinical
models and displayed activities that have many beneficial effects, such as chemopreventative, anti-cancer, anti-mutagenic, anti-inflammatory, liver protection, cellular
stress preventive, iron-chelating abilities and is even protective against UV rays [173181]. Specific to neurodegeneration, DIB was shown to prevent neuronal loss in the
hippocampus and improve memory deficits in a transgenic prion-diseased mouse model
and in a transgenic mouse model of tauopathy-frontotemporal dementia [180].
Interestingly, DIB was also explored in models of cancer with various
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combination drug approaches [178, 179]. The effect of a DZ/DIB combination treatment
was not addressed.
We decided to investigate the beneficial effects of a DZ/DIB combination in an
AD context, because in separate studies these drugs prevent progression of
neurogenerative pathology in preclinical rodent models [172, 180]. We tested the
DZ/DIB combination treatment with TgF344-AD (Tg-AD) rats and their wild type (WT)
littermates (Fig 4.1). Tg-AD rats were previously described in Chapter 2 section 2.3.1.
In my studies I focused on cognitive deficits assessed with RAM. In addition, in a
subset of female rats, I also compared the transcriptome via RNAseq at 4- and 11months for genotype and treatment effects. The 4-month timepoint was chosen for
RNAseq to reveal changes in pre- or early- AD pathology for potential biomarkers. Cotreatment with DZ/DIB has multiple mechanisms of action that affect biological networks
rather than a single target in a disease that has multiple hallmarks. At 4-months and 11months of age, I accessed AD-related cognitive deficits and transcriptome changes in
the Tg-AD rats. The DZ/DIB co-treatment mitigated spatial memory deficits in the 11month Tg-AD rats. Comparison between 4-month WT and Tg-AD untreated rats
revealed two potential early biomarkers for AD. Overall, my studies used a novel cotreatment with repurposed drugs to treat AD with a polypharmacology strategy.

4.3. MATERIALS AND METHODS
4.3.1 TgF344-AD transgenic rat model of AD – described in Chapter 2 section 2.3.1.
4.3.2. Experimental Design
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A total of 54 rats [WT n = 30 (15 females, 15 males), Tg-AD n = 24 (10 females, 14 males)]
were used in the RNAseq and RAM analysis for the DIB/DZ study. At 52 days rats began
a co-treatment of DZ (10 mg/kg bw) and DIB (200 mg/kg bw) that was administered in
rodent chow (Research Diets Inc. NJ) until respective sacrifice date at 4 months or 11
months of age. All RNAseq samples that were outsourced and all rats that completed
RAM behavior were included in the analysis.
4.3.3. Cognitive behavior assessment with the passive radial 8-arm maze - described
in Chapter 2 section 2.3.8.
4.3.4. RNAseq analysis
Hippocampal tissue was used for RNAseq analysis outsourced to the UCLA Technology
Center for Genomics & Bioinformatics services. A total of 25 samples with five 11 months
WTNT and TGNT females and five 4 month WTNT, TGNT, TGTR females were
compared. RNA processing and analysis is described in Chapter 2 section 2.3.6.
4.3.5. Statistics - described in Chapter 2 section 2.3.10.
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Figure 4.1 Schematic representation of the experimental design

Figure 4.1 (A) Time line of the progression of the AD pathology
developed by Tg-AD rats. We preformed analysis at 4 and 11 months.
(B) Rat groups used in the study. (C) Assessments at 4 months (D)
Assessments at 11 months

100

4.4. Results
4.4.1. Tg-AD 4-month old rats do not exhibit spatial memory deficits and DZ/DIB cotreatment improves spatial memory in 11-month Tg-AD rats
RAM behavioral task was used to assess short-term working memory performance on 4month old and 11-month old Tg-AD and WT rats. Sexes were combined for a total of four
groups: WTNT and TGNT as well as WTTR and TGTR (DZ/DIB treated). A two-way
ANOVA of RAM performance at the 4-month and 11-month time point was performed for
the four groups, considering genotype (WT vs. Tg-AD) and drug treatment (DZ/DIB cotreatment vs. no treatment), using the Sidak’s post-hoc analysis. We assessed
hippocampal dependent cognition by measuring the number of errors for light working
memory load which is defined as the number of errors made during the first four unique
arms, and heavy working memory is defined as the number of errors in the final four
unique arms. In both cases, errors are defined as the re-entering of a previously baited
arm before completing the task.
The 4-month RAM assessment showed no significant differences in light working
memory load irrespective of genotype or treatment, analyzed using an ordinary two-way
ANOVA (F(1,57) = 2.645, p = 0.11 for genotype), (F(1,57) = 0.4337, p = 0.51 for treatment).
Similar results were observed for the heavy working memory load (F(1,58) = 1.498, p = 0.23
for genotype), (F(1,58) = 1.695, p = 0.20 for treatment) (Fig 4.2).
A second round of RAM was performed at 11-months of age using a subset of the
same cohort that performed RAM at 4-months of age and were not sacrificed. This
analysis determined whether there were any cognitive deficits at the 11-months of age.
We found that by 11-months, transgenic rats performed significantly worse than age101

matched wild-type rats in light working memory load, analyzed by ordinary two-way
ANOVA (F(1,39) = 12.25, p < 0.01 for genotype). Sidak’s post-hoc tests showed a
significant post-hoc difference between WTNT and TGNT rats (p < 0.01). DZ/DIB cotreatment significantly improved the performance of all treated rats, independent of
genotype (F(1,39) = 6.089, p = 0.02 for drug treatment), with a post-hoc difference found
between TGNT and TGTR (p = 0.05). No significant differences in heavy working memory
load were observed at 11-months irrespective of genotype or treatment. This suggests
that the heavy working memory load is challenging, the RAM task becomes increasingly
difficult for all rats to complete, requiring great cognitive ability to remember a large
number of arms.
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Figure 4.2 DZ/DIB cotreatment mitigates spatial working memory deficits

A.

B.

C.

D.

E.

Figure 4.2 (A) RAM with the arms labelled 1 – 8 (created with BioRender.com)
(B) 4 month light working memory errors. (C) 4 month heavy working memory
errors (D) 11 month light working memory errors. (E) 11 month heavy working
memory errors. Significant differences were observed only in 4.2D showing
improved behavior in TGTR rats. Significance estimated with a one-tailed
Welch’s t test, and p values are shown above bar graphs.
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4.4.2. Transcriptome changes in DZ/DIB treated compared to untreated Tg-AD
female rats
Differences in the expression of the APP and PSEN1 genes between untreated
WT and Tg-AD was expected, because the Tg-AD rats express APPswe and PS1E9
mutations driven by the prion promoter, at 2.6- and 6.2-fold higher levels than the
respective endogenous rat protein). The RNAseq showed that APP and PSEN1 are
upregulated at both 4 and 11 months (Table 4.1 A and B).
The RNAseq data also showed a ~2.0 fold decrease in EGR2 and a ~3.9 fold
increase in HIST1H2AA expression in female TGNT rats compared to WTNT at 4-months
of age (Table 4.1A). There was a ~2.0 fold increase in GFAP and a ~182.1 fold increase
in RN7SL1 expression in female TGNT rats compared to WTNT at 11-months of age
(Table 4.1B). TGTR rats saw an increased fold change in expression for nine genes: TTR
(~65.7), OLFM3 (~1.6), CNTN6 (~1.8), NDST4 (~1.9), IRF6 (~2.8), SLC17A6 (~1.8), KL
(~31.3), NPSR1 (~4.2) and CLEC3A (~15.4) compared TGNT at 4 months (Table 4.1C).
RN18S was decreased ~1.6 fold in TGTR rats compared TGNT at 4 months (Table 4.1C).
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Table 4.1A
4-month Females Transgenic AD Not Treated vs. Wild-Type Not Treated
Gene symbol

Fold change

P Value

FDR

APP
PSEN1
EGR2
HIST1H2AA

 1.99
 2.11
 2.02
 3.87

1.82E-37
2.28E-29
3.50E-06
1.83E-07

3.12E-33
1.96E-25
0.015
0.001

TGNT RPM TGNT RPM WTNT RPM WTNT RPM
mean
S.E.M
mean
S.E.M.
2175.8
74.1
3.9
2

66.4
3.8
0.5
0.2

1107.8
35.4
8
0.5

20.3
1.1
0.7
0.1

Table 4.1B
11-month Females Transgenic AD Not Treated vs. Wild-Type Not Treated
Gene symbol

Fold change

P Value

FDR

APP
PSEN1
GFAP
RN7SL1

 2.09
 2.22
 1.97
 182.08

2.37E-07
1.83E-14
1.68E-06
2.58E-06

0.002
3.50E-10
0.009
0.011

TGNT RPM TGNT RPM WTNT RPM WTNT RPM
mean
S.E.M
mean
S.E.M.
2897.9
66.1
1983
6692.8

73.1
3.1
130.1
6638.8

1383.4
30.1
1002
36.7

72.3
1.9
75
5.4

Table 4.1C
4-month Females Transgenic AD DZ-DIB Treated vs. Transgenic AD Not Treated
Gene symbol

Fold change

P Value

FDR

TTR
OLFM3
CNTN6
NDST4
IRF6
SLC17A6
KL
NPSR1
RN18S
CLEC3A

 65.69
 1.60
 1.82
 1.85
 2.78
 1.82
 31.25
 4.15
 1.60
 15.38

1.81E-08
1.04E-05
3.57E-06
1.42E-05
2.06E-05
1.46E-08
4.22E-05
1.20E-05
6.40E-10
5.80E-06

1.04E-04
0.029
1.50E-02
0.03
0.039
1.04E-04
0.06
0.029
1.10E-05
0.012

TGTR RPM TGTR RPM TGNT RPM TGNT RPM
mean
S.E.M
mean
S.E.M.
9.7
8.5
68.9
317.1
14
79.7
9.2
119.2
142
8.7

0.7
0.5
2
8.5
0.7
4.4
0.3
4.2
5.5
0.9

17.1
9.1
47.6
281.7
11.8
94.4
7.9
115.9
125.7
5.8

1.2
1.1
1.9
15.2
0.7
5
0.2
8.4
10.2
0.6

Table 4.1 RNA sequence analysis for differentially expressed genes in (A) 4 month female transgenic AD not
treated rats compared to age-matched wild-type female rats, (B) 11 month female transgenic AD not treated rats
compared to age-matched wild-type not treated female rats, and (C) 4 month transgenic AD DZ-DIB treated rats
compared to age-matched transgenic AD- not treated female rats. Genes are listed with significant fold change
difference in expression. Upregulation in gene expression is represented with an up-arrow and downregulation in
gene expression represented with a down-arrow and bolded. p values, false discovery rates (FDR), means, as well
as standard errors of the mean (s.e.m) for RPMs (reads per million). All genes with an FDR under 0.05 were
included.
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4.5. DISCUSSION
My study investigated the prospect of repurposing DZ/DIB combination to treat AD
using Tg-AD rats at 11 months of age, because the pathology resembles an early AD
phenotype in an age-dependent progressive manner as described in our previous studies
[28]. AD is a complex disease that is not uniform in patients with multiple roads of entry,
there will need to be multiple drugs to address different aspect of AD pathology. Unique
multi-target drug interactions have the potential to influence a larger spectrum of
pathologies, and potentially compensatory or redundant mechanisms.
DZ has been used for decades for its cardioprotective effects, so it is a welltolerated and efficacious drug, therefore a great candidate for repurposing [168]. DZ’s
mechanism against apoptosis may be helpful in preventing neuronal loss in later stages
of AD, but it was not robustly seen at 11-months of age. DIB is a promiscuous drug with
affinity to many targets and likely some still unknown. Some of the suggested
mechanisms for DIB are inhibition of the unfolded protein response, increase in activity
of protective transcription factors, induction of cell cycle arrest, and reducing expression
of androgen receptors [180-182]. DIB has been shown to be neuroprotective specifically
to the hippocampus in neurodegenerative models [180], but to our knowledge not in an
AD animal model. Co-treatment of these two drugs widens the reach of
polypharmacology, with multiple mechanisms of action such as DZ balancing calcium
overload, DIB’s relief of cellular stresses through eukaryotic Initiation Factor 2 (eIF2) and
activation of nuclear factor erythroid 2–related factor 2 (Nrf2), and inhibition of c-Jun Nterminal kinases (JNK) to prevent oxidative damage. The RAM analysis was performed
with male and females, and the RNAseq analysis included a subset of females only.
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For the RAM at 4 months in both light and heavy working memory, there were no
significant differences indicating that no short term spatial working memory deficits are
present. The original study of the Tg-AD model looked at 6 months and did see early
signs of pathology, such as soluble Aβ1–40, gliosis and phosphorylated tau [27], but our
studies including those performed by Giovanni Oliveros, another graduate student in our
lab. Briefly, Giovanni demonstrated that DZ/DIB cotreatment reduced Aβ plaque burden,
reduced hyperphosphorylated tau, and increased eIF2α levels in the hippocampus.
DZ/DIB cotreatment did not reduce gliosis, prevent GCL neuronal loss, or alter EGR2
levels. The RAM behavior focused on specifically hippocampal dependent spatial
learning. At 11-months of age spatial light working memory deficits were mitigated by the
DZ/DIB co-treatment in TGTR vs TGNT and there was an overall treatment benefit across
all groups indicating an effect beyond genotype.
The RNAseq analysis between female TGNT and WTNT showed significant
changes at 4-months of age. Both genes are involved in genetic regulation, Histone H2A
type 1-A (HIST1H2AA) and Early Growth Response 2 (EGR2). HISIT1H2AA is a subtype
of the H2A histone which is one of five histones that package DNA to make up the
nucleosome important for gene regulation [183]. Histones regulate gene expression, and
they are post-transcriptionally modified with mechanisms such as acetylation,
methylation, phosphorylation and ubiquitination [184]. A study using human frontal cortex
brain tissue found that H2A was less ubiquitinated in AD brain tissue compared to age
matched controls [185], so the increase in HISIT1H2AA could result from a reduction in
ubiquitin/proteasome degradation. Further studies would be required to conclude if this
upregulation is a result of less ubiquitin/proteasome degradation.
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EGR2, is an inducible transcription that has been studied in the CNS for its role in
subtle changes in gene expression [186]. Studies on EGR2 suggest that EGR2 plays a
role in regulating the activity of Nuclear Factor Kappa B (NF-κB), which has been
extensively studied in the context of AD because of its involvement in innate immune
dysregulation [187, 188].
To no surprise, genes from the Tg-AD model that are overexpressed are Amyloid
Precursor Protein (APP) and Presenilin 1 (PSEN1) at both 4- and 11-months of age, as
well as GFAP being upregulated only at 11-months of age indicating astrogliosis with
increased neuroinflammation.
The highest fold difference in the RNAseq that was observed at 11-months of age
between the TGNT and WTNT rats was the RNA component of the signal recognition
particle 7SL1 (RN7SL1). RN7SL1 is an important component in targeting proteins for
transport throughout the cell, and too much of RN7SL1 leads to increased inflammation
[189, 190]. This 182-fold increase in TGNT rats may be due to impaired transport or
neuroinflammation.
The RNAseq analysis in TGTR vs TGNT rats was performed at 4 months of age
to assess how the DZ/DIB co-treatment may alter gene expression in early AD
pathogenesis. Genes that were upregulated are connected to cognition, neurogenesis,
differentiation, synaptic plasticity, apoptosis, and amyloid toxicity. Some of the genes that
were up-regulated in TGTR vs TGNT rats were: (1) Transthyretin (TTR). TTR is a
multifunctional protein that has many roles in the CNS including cognition and
neurogenesis via interaction and transport of thyroxine and retinol (Vitamin A) [191][192].
TTR has also been found to be neuroprotective against AD because of its affinity to bind

108

to Aβ40 to prevent Aβ toxicity [193]. (2) Olfactomedin 3 (OLFM3), which is important for
differentiation in the brain and retina [194]. (3) Contactin 6 (CNTN6) that plays a role in
axonal formation for the mossy fibers within the hippocampus during development and it
also is thought to be involved in apoptosis for neuron survival [195]. (4) N-deacetylase
and N-sulfotransferase 4 (NDST4) identified a markers for recently differentiated neural
cells [196]. (5) Interferon regulatory factor 6 (IRF6) which is relevant to epithelial tissue,
where it mediates differentiation and helps regulate apoptosis [197, 198]. (6) Solute
Carrier Family 17 Member 6 (SLC17A6) that enables the activity of glutamate transporters
and is important for synaptic plasticity and expression correlated to cognitive function
[199, 200]. (7) Klotho (KL) variants shown to mitigate amyloid burden derived from
APOE4 pathways [201]. (8) Neuropeptide S receptor 1 (NPSR1) is important in
hippocampal function and promotes synaptic plasticity [202]. (9) Rn18s 18S ribosomal
RNA (RN18S) and C-type lectin domain family 3 member A (CL3C3A) induce changes in
transcription that are less clear, because respectively one has ribosomal function while
the other is known to bind to heparin [203, 204].
The following upregulated genes after DIB/DZ treatment are known to decline with
AD severity and/or ageing: SLC17A6, TTR, KL and NDST4 [200, 205-207]. It is possible
that the pathology that contributes to a decline in the transcriptome of the TGNT may
have been mitigated by the DZ/DIB co-treatment at 4-months of age.
In summary, at 4-months of age TGNT rats were pre-symptomatic showing no
signs of spatial memory deficits compared to WTNT rats. In addition, I identified two
potential biomarkers for pre-symptomatic AD: EGR2 and HISIT1H2AA. At 4-months of
age TGTR rats exhibited an upregulation of genes known to be downregulated in AD.
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Some of these genes are involved in neurogenesis and other protective mechanisms.
The novel DZ/DIB co-treatment provides evidence for the neuroprotective nature of
these drugs, and also the benefits of drug repurposing and polypharmacology.
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5.1 Overview
AD has been around for over a century, and we are still struggling to find an
effective treatment for it. Investigators have looked into treating many hallmarks of AD
pathology such as targeting Aβ, altering amyloid cleavage, dephosphorylation of tau and
anti-inflammatory drugs [68, 164, 208]. I focused my studies on inflammation, which
during AD pathogenesis can act as a friendly fire, meaning that the immune inflammatory
response in the brain is actually causing harm because it does not resolve [209]. Early
epidemiological studies pointed to NSAIDs to prevent AD, but with many adverse side
effects and failures in clinical trials it has been very challenging to keep pursuing NSAIDs
as a viable therapeutic for reducing risk or preventing AD [47]. NSAIDs work by inhibiting
the production of prostaglandins, which have many functions including inflammation,
nociception, sleep, and vascular related [31].
I focused on PGD2 which is known to be the most abundant prostaglandin in the
brain and it’s brain synthase LPGDS is the second most abundant protein in the CSF [84].
My prostaglandin analysis also showed that PGD2 was the most abundant in the
hippocampus. PGD2 has not been studied enough for its inflammatory functions, but its
inflammation cascade is well defined in airway inflammation in mast cells [210]. I chose
to study the PGD2 signaling pathway in an AD model that presented a large spectrum of
pathology including amyloid, tau, spatial deficits, neuronal loss and gliosis in an agedependent and progressive manner [27]. My studies provide novel and ample information
on PGD2 and its receptors in the hippocampus.
5.2 DP2 and Neurons in the GCL
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I found that in the hippocampus, DP2 co-localized primarily with NeuN, a marker
for mature neurons. Based on known classes of neurons located within the hippocampal
subregions, DP2 appears to be present in pyramidal, granular, and interneurons.
Neuronal loss in Tg-AD rats was apparent in the DG hippocampal area, thus I analyzed
the DG subregions and established that neuronal loss was prominent in the GCL.
Bordering the GCL and HL is the sub granular cell layer, which is the sight of
neurogenesis in rodents. The beneficial process of neurogenesis could be impaired in the
Tg-AD rats thus contributing to spatial deficits. I propose that DP2 inhibition could be an
effective therapeutic strategy against DP2 driven inflammation.
5.3 DP1 and Microglia Phenotype in the hippocampal Hilar subregion
Within the hippocampus, I investigated DP1 co-localization with Iba1, a microglial
marker. I established that phagocytic/ameboid microglia were predominantly located in
the hippocampal hilar subregion. This complemented my amyloid plaque staining, as I
identified significant greater numbers of plaques in the hilar subregion than in others.
Additionally, compared to WT rats the Tg-AD rats had a greater number of DP2/Iba1 colocalization in the hilar region microglia. The hilar region has many interneurons that are
important in DG circuitry, which is important for sending information to the CA3. It is
unclear if DP1 activation or inhibition would be beneficial to AD. Given that DP1 activation
promotes sleeping, DP1 inhibition would likely lead to adverse sleep outcomes.
5.4 Human polymorphisms linked to NSAID treatment efficacy and the PGD2
signaling option
The NSAID treatment option for AD could still be considered since there seems to
be a benefit, besides the results from clinical trials. However, the adverse side effects are
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clearly a concern. These adverse side effects in only some of the patients may be
explained by polymorphisms in the COX genes. I propose that individuals with the highest
inflammatory profile would benefit the greatest from NSAID use if it were to be revisited
in future clinical trials. Downstream of NSAIDs, PGD2 therapeutics may be a more direct
anti-inflammatory target and possibly generate much less renal, gastrointestinal and
vascular complications.
5.5 Novel Therapeutics for AD
I demonstrated that treatment with a DP2 antagonist mitigated much of the AD
pathology in the Tg-AD rats, such as spatial learning deficits, plaque burden, neuronal
loss and microgliosis. Timapiprant is not an entirely novel drug, but I chose to repurpose
its anti-inflammatory mechanism for neuroinflammation [89, 211-213]. Many DP2
antagonists have been developed because of the role of DP2 in airway inflammation, thus
these could also be explored in neuroinflammatory diseases if they can cross the BBB
[64].
Additionally, I demonstrate that in a separate cohort of Tg-AD rats, DZ/DIB cotreatment diminishes cognitive deficits and causes transcriptome changes. DZ/DIB cotreatment targets biological networks rather than a single target [70, 165]. DZ has long
been used as a cardioprotective therapeutic, and DIB is used in preclinical models. Both
of these drugs administered individually induce improvements in neurodegenerative
disease preclinical models [169, 172, 180]. DZ/DIB co-treatment benefits spatial memory
in 11-month Tg-AD rats and induces upregulation of genes that are downregulated in AD
and/or ageing. In conclusion, the two novel AD treatments tested in my studies open the
window for potential new treatments for AD.
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6.1 Overview
DP2 antagonists have been explored in clinical trials mainly for diseases of airway
inflammation and alopecia. To my knowledge there are no DP2 antagonists used in
neurodegenerative diseases. Timapiprant, the DP2 antagonist used in my studies was
chosen from a list of 12 DP2 antagonists. Only 2 of the 12 were predicted in silico to
permeate the BBB. There is a need to determine if timapiprant crosses the BBB. To
address crossing of the BBB in vivo, oral administration of timapiprant would be given to
rats at 15 mg/kg bw, which is the dosage used in my studies describe in Chapter 2. Upon
timapiprant administration, the rats would be sacrificed at three timepoints: 15-min, 60min and 120-min. Samples would be purified from whole brain tissue and blood plasma.
These samples would be analyzed via UPLC-MS/MS to detect the levels of timapiprant
in the brain and plasma. The initial goal would be to determine if timapiprant crosses the
BBB. In addition, more sophisticated pharmacology studies could determine the degree
of penetration and uptake following the method outlined in [214]. Studies often use
different drug administration techniques, such as intravenous injection or in situ brain
perfusion, both of which have less variability and avoid drug metabolism by the liver [215].
However, oral administration best mimics my studies described in Chapter 2, and
translates best to clinical practice. As demonstrated in my studies (Chapter 2), timapiprant
mitigated AD pathology, so either (1) timapiprant does penetrate the BBB, or (2) there is
a peripheral benefit from systemic inflammation, or (3) there is an alternative peripheral
benefit.
6.2 cAMP signaling induced by DP1 and DP2 activation in neurons and glia
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The mechanism of PGD2 signaling and its contribution to neuroinflammation is
poorly understood. I investigated DP1 distribution within different microglia phenotypes
(ramified, reactive, amoeboid), but not with specific M1 or M2 markers. I investigated DP2
co-localization with hippocampal neurons in vivo, but signaling in neurons was not
investigated. DP1 and DP2 work antagonistically in the CNS through cAMP signaling.
PGD2 signaling through DP1, activates the PKA pathway where cAMP is neuroprotective
by directly increasing levels of cAMP response element binding protein (CREB). DP2
signaling has been meticulously studied in human papilla cells, leading to clinical trials for
alopecia with Setipiprant [216, 217]. Increased levels of CREB and specifically
phosphorylated CREB (p-CREB) leads to increased BDNF with benefits such as neuronal
survival, improved cognition, anti-inflammation [218]. BDNF levels are decreased in the
hippocampus of AD patients, where neurodegeneration is present, and the lack of BDNF
likely explains neurodegeneration [219]. DP2 inhibition as performed in my studies, has
the potential to lead to a downstream increase in BDNF, thus explaining neuronal survival
in TGTR rats.
To determine the mechanisms of PGD2 signaling in neurons and microglia I
propose the following experiments. I previous established that HMC3 cells express DP1
and SY5Y-APP cells both DP1 and DP2. In vitro analysis of polarized HMC3 microglia
cell lines: (1) insult with H2O2, Glutamate, Aβ and PGJ2 (2) use DP1 agonists and
antagonists to determine if DP1 signaling is protective (3) use knockdowns of DP1 and
HPGDS [220]. Upon treatment, HMC3 will be processed for (1) immunocytochemistry to
establish, using specific microglia markers, which microglia phenotypes express DP1 do
HMC3 cells and (2) ELISA assays to determine anti- or pro-inflammatory cytokine profiles
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(3) and measure downstream markers for DP1 signaling such as CREB and BDNF.
Therefore, SY5Y-APP neuron-like cells that overexpress APP will be given similar insults
as the HMC3 cells to assess cell death or viability [221, 222]. PGD2 signaling can work
in either a paracrine or autocrine manner [223-225]. Future directions could investigate
how DP1 and DP2 signaling affects microgliosis and neuronal survival, and if the effects
can work through a paracrine mechanism.
Insulin resistance and cognitive decline is impaired in AD patients [226, 227]. One
of the biggest risk factors for AD is type 2 diabetes, and diabetes correlates so highly with
AD that some cases driven by insulin resistance in AD are often referred to as “diabetes
of the brain” or “type 3 diabetes” [3, 227]. Insulin is known to be impaired in the brain of
AD patients through the insulin–PI3K–AKT axis [228]. This type 3 diabetes leads to
neuroinflammation; thus, it would be novel to determine if PGD2 signaling has a role in
neuroinflammation, being the most abundant prostaglandin in the brain. Additionally, DP2
is suggested to be involved in PI3K signaling [229].

I will investigate the potential

connection between DP2 signaling and insulin signaling.
6.3 PGD2 pathway proteins in Tg-AD Rats: Further hippocampal IHC analysis
Neurons are identified by multiple characteristics such as neurotransmitter
(glutamatergic or GABAergic), regional location, synapse, etc [230]. In my studies I
determined the DP2/NeuN co-localization based on hippocampal subregions. However,
it is important to determine co-localization of DP2 with LPGDS, COX-1 and COX-2 on
hippocampal neurons. Additionally, it is important to investigate if DP2 expression is
different on different types of neurons based on (1) neurotransmitters (2) synapses (3)
degree of plasticity (3) degenerating neurons and (4) newly generated neurons. DP1 is
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also expressed in hippocampal neurons [132], but my studies found DP1 mostly in
microglia. However, co-localization of DP1 and DP2 in the same cell may be interesting
to investigate given their antagonistic cAMP signaling.
6.4 Investigate Sox-2 and PGD2 signaling related to DG neurogenesis
Sox-2 is a transcription factor involved in proliferation, differentiation and
neurogenesis [20]. Sox-2 interacts with DP2 in other cell types outside of the CNS, such
as Sertoli cells present in the seminiferous tubules of the testes [22, 23, 38]. However, no
studies have investigated the relationship between DP2 and neurogenesis. It is important
to determine if DP2 is expressed on newly generated neurons, if it is involved in
neurogenesis in the hippocampal DG, and if SOX-PGD2 signaling plays a role in
neurogenesis. To investigate this possibility (1) DP2, Sox-2 and LPDG2 should be
analyzed by IHC in vivo in the subgranular cell layer of the DG. An in vitro analysis after
neuronal differentiation is induced by neurodazine and neurodazole[231] (1) determining
DP2, SOX2 and LPGS expression (2) determine the impact of DP2 agonists and
antagonists on this process.
6.5 Human Brain Tissue
Based on the polymorphisms described in Chapter 3, AD patients that have
excessive prostaglandin signaling may be in a more inflammatory state. It would be
interesting to obtain the genomic profiles of AD patients that are available at the brain
banks to determine the frequencies of the (1) protective COX-2 polymorphism, (2) DP1
haplotype that increases expression, (3) DP2 polymorphism that increases expression,
and (4) LPGDS polymorphism that associates with atherosclerosis. Based on the
frequencies that may reach statistical significance between AD tissues and controls, IHC
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experiments can be carried-out to determine the expression of these markers in human
AD tissue.

6.6 Summary
I demonstrated that antagonism of the prostaglandin D2 receptor was protective in the
Tg-AD rat model There is still a lot that is unknown about PGD2 signaling and the
mechanism of its involvement in AD. With these proposed experiments I would determine
if timapiprant is a viable candidate for clinical trials, better understand PGD2 signaling in
neurons and glia, determine if PGD2 has a role in insulin resistance, determine if DP2
has a role in neurogenesis and determine the frequency of polymorphisms in PGD2
genes in brain banks.
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Figure 6.1 Summary Scheme

B.

A.

C.

Fig. 6.1 Summary Scheme. (A) I demonstrated that timapiprant, a dp2 antagonist, mitigated AD
like pathology including microgliosis. DP2 is primarily expressed on neurons and was not
detected in microglia. TGTR had less DP1 colocalized microglia compared to TGNT. (B) I
showed the benefit of polypharmacology using DZ/DIB cotreatment. AD is a multifaceted disease
so it is likely that a multi-target therapy will have greater efficacy. (C) NSAIDs have long been
implicated in AD prevention, but they fail in clinical trials. Screening for polymorphisms in the
COX1/2 genes would likely produce the best candidates for preventing or delaying AD with
NSAIDs.
(created with BioRender.com).
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